NZ622466B2 - Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof - Google Patents

Abstract

Provided are topical veterinary parasiticidal compositions comprising at least one isoxazoline active agent of general formula (I), wherein the variables are as defined in the specification. A preferred active agent is 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalanecarboxamide. The compositions also comprise a pharmaceutically acceptable carrier, one of the preferred carriers is a dialkyl ester of a C10-C22 dicarboxylic acid, such as diethyl sebacate, dibutyl sebacate or diisopropyl sebacate. zolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthalanecarboxamide. The compositions also comprise a pharmaceutically acceptable carrier, one of the preferred carriers is a dialkyl ester of a C10-C22 dicarboxylic acid, such as diethyl sebacate, dibutyl sebacate or diisopropyl sebacate.

Description

TITLE OF THE INVENTION TICIDAL COMPOSITIONS COMPRISING AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES THEREOF.

CROSS REFERENCE TO RELATED APPLICATIONS This ation claims the benefit of priority to US. Provisional Application No. 61/533,308 filed September 12, 2011, which is incorporated herein by nce in its entirety.

FIELD OF THE INVENTION The present invention provides l veterinary compositions comprising at least one isoxazoline active agent for controlling ectoparasites and endoparasites in animals; the use of these compositions against ectoparasites and/or endoparasites, and methods for ting or treating parasitic infections and infestations in animals.

BACKGROUND OF THE INVENTION Animals such as s and birds are often susceptible to parasite infestations/infections. These tes may be ectoparasites, such as insects, and endoparasites such as filariae and other worms. Domesticated animals, such as cats and dogs, are often infested with one or more of the following ectoparasites: - fleas (e.g. Ctenocephalz’des spp., such as Ctenocephalz’desfelz’s and the like); - ticks (e.g. ha’pz’cephalus spp., Ixodes spp., Dermacentor spp., Amblyoma spp., and the like); - mites (e.g. Demodex spp., Sarcoptes spp., 0t0dectes spp., and the like); - lice (e.g. dectes spp., Cheyletiella spp., Lignonathus spp. and the like); - mosquitoes (Aedes spp., Culux spp., Anopheles spp. and the like); and - flies (Hematobz'a spp., Musca spp., Stomoxys spp., Dematobz'a spp., mz'a spp. and the like).

Fleas are a particular problem because not only do they adversely affect the health of the animal or human, but they also cause a great deal of psychological stress. Moreover, fleas are also vectors of pathogenic agents in animals and humans, such as dog tapeworm (Dipylz'dz'um caninum).

MER ll-l79PCT rly, ticks are also harmful to the physical and psychological health of the animal or human. However, the most serious m associated with ticks is that they are the vector of pathogenic agents in both humans and animals. Major diseases which are caused by ticks include borrelioses (Lyme disease caused by Borrelz'a burgdorferz’), babesioses (or piroplasmoses caused by Babesz'a spp.) and tsioses (also known as Rocky Mountain spotted fever). Ticks also release toxins which cause ation or paralysis in the host. Occasionally, these toxins are fatal to the host.

Likewise, farm animals are also susceptible to parasite infestations. For example, cattle are affected by a large number of parasites. A parasite which is very ent among farm animals is the tick genus ha’pz’cephalus, ally those of the species microplus (cattle tick), decoloratus and annulatus. Ticks such as ha’pz’cephalus microplus (formerly Boophz'lus microplus) are particularly difficult to control because they live in the pasture where farm animals graze. This species of ticks is considered a one-host tick and spends re and adult stages on one animal before the female engorges and falls off the host to lay eggs in the environment. The life cycle of the tick is approximately three to four weeks. In addition to cattle, ha’pz’cephalus microplus may infest found on buffalo, horses, donkeys, goats, sheep, deer, pigs, and dogs. A heavy tick burden on animals can decrease production and damage hides as well as transmit diseases such as osis le fever”) and anaplasmosis caused by protozoan parasites.

Animals and humans also suffer from rasitic infections including, for example, helminthiasis which is most frequently caused by a group of parasitic worms categorized as cestodes (tapeworm), nematodes worm) and odes (flatworm or flukes). These tes adversely affect the nutrition of the animal and cause severe economic losses in pigs, sheep, horses, and cattle as well as affecting domestic animals and poultry. Other parasites which occur in the gastrointestinal tract of animals and humans include Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Toxocara, Toxascaris, Trichiris, Enterobius and parasites which are found in the blood or other tissues and organs such as filarial worms and the extra intestinal stages of Strogyloides, Toxocara and Trichinella.

Recently, isoxazole and isoxazoline-containing compounds have been demonstrated to be effective t parasites that harm animals. For example, US 2010/0234219 Al (to DuPont) MER ll-l79PCT discloses oline nds according to Formula (1) below, which are active against ectoparasites and/or endoparasites.

In addition, hed patent application nos. US 2010/0254960 Al, A2, WO 23855 A2, Al, US795 l 828 & US7662972, US 2010/0137372 Al, US 20lO/Ol79l94 A2, US 2011/0086886 A2, US 2011/0059988 Al, US 20lO/Ol79l95 Al and WO 2007/075459 A2 and US. Patent Nos. 7,951,828 and 7,662,972 describe various other parasiticidal isoxazoline compounds. describes topical localized oline formulations comprising glycofurol.

Notwithstanding the compositions comprising isoxazoline active agents alone or in combination with other active agents described in the documents above, there is a need for veterinary compositions and methods with improved efficacy, bioavailability, and spectrum of coverage to protect animals against rasites and/or ectoparasites. Optimal compositions should e contact and/or systemic activity, be efficacious, have a quick onset of activity, have a long duration of activity, and be safe to the animal recipient and their human owners. This invention ses this need.

INCORPORATION BY REFERENCE Any foregoing applications, and all documents cited therein or during their ution (“application cited documents”) and all documents cited or referenced in the ation cited documents, and all documents cited or referenced herein (“herein cited documents”), and all documents cited or referenced in herein cited documents, together with any manufacturer’s instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any nt incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.

Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these s form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this ation.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

SUMMARY OF THE INVENTION One aspect of the invention provides a topical nary composition for treating or preventing a parasitic infection or infestation in an animal comprising: a) at least one isoxazoline active agent of Formula (I): (I) wherein: A1, A2, A3, A4, A5 and A6 are independently selected from the group consisting of CR3 and N, provided that at most 3 of A1, A2, A3, A4, A5 and A6 are N; B1, B2 and B3 are independently selected from the group consisting of CR2 and N; W is O or S; R1 is C1-C6 alkyl, C2-C6 l, C2-C6 l, C3-C6 cycloalkyl, C4-C7 ycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R6; each R2 is independently H, halogen, C1-C6 alkyl, C1-C6 kyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1- C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, C2-C4 alkoxycarbonyl, —CN or —NO2; each R3 is independently H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3- C6 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 lamino, —CN or —NO2; R4 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C4-C7 cycloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl; R5 is H, OR10 , NR11 R12 or Q1; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each ally substituted with one or more substituents independently selected from R7; or R4 and R5 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and O, said ring optionally substituted with 1 to 4 substituents ndently ed from the group consisting of C1-C2 alkyl, halogen, —CN, —NO2 and C1-C2 alkoxy; each R6 is ndently halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 hio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, —CN or —NO2; each R7 is independently halogen; C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 alkylamino, C2-C8 dialkylamino, C3-C6 cycloalkylamino, C2-C7 alkylcarbonyl, C2-C7 alkoxycarbonyl, C2-C7 alkylaminocarbonyl, C3-C9 dialkylaminocarbonyl, C2-C7 haloalkylcarbonyl, C2-C7 koxycarbonyl, C2-C7 haloalkylaminocarbonyl, C3-C9 dihaloalkylaminocarbonyl, hydroxy, —NH2, —CN or —NO2; or each R8 is independently halogen, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 mino, C2-C6 dialkylamino, C2-C4 alkoxycarbonyl, —CN or — NO 2; each R9 is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 lamino, —CN, —NO2, phenyl or pyridinyl; R10 is H; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one of more halogen; R11 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C4-C7 cycloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl; R12 is H; Q3; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally tuted with one or more substituents independently selected from R7; or R11 and R12 are taken er with the nitrogen to which they are ed to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and O, said ring optionally substituted with 1 to 4 substituents independently selected from the group consisting of C1-C2 alkyl, halogen, —CN, —NO2 and C1-C2 alkoxy; Q1 is a phenyl ring, a 5- or 6-membered heterocyclic ring, or an 8-, 9- or 10-membered fused bicyclic ring system optionally containing one to three heteroatoms selected from up to 1 O, up to 1 S and up to 3 N, each ring or ring system optionally substituted with one or more tuents independently selected from R8; each Q2 is independently a phenyl ring or a 5- or ered heterocyclic ring, each ring optionally substituted with one or more substituents independently ed from R9; Q3 is a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more tuents independently selected from R9; and n is 0, 1 or 2; and b) a pharmaceutically acceptable carrier that is suitable for the application to the skin of an animal, wherein said carrier comprises a dialkyl ester of a C10 -C22 dicarboxylic acid.

The present invention is directed to l compositions comprising at least one isoxazoline, alone or in combination with other active agents, and their use to control parasites in or on warm-blooded s and birds. In accordance with this invention, it has been ered that these compositions generally show desirable bioavailability, and can provide contact and/or systemic activity. The compositions also provide desirable safety profiles toward the warmblooded and bird animal recipients. In addition, it has been ered that a single administration of such compositions generally provides potent activity against one or more ectoparasites, while also tending to provide fast onset of activity, long duration of activity, and/or desirable safety profiles.

The invention encompasses uses or nary uses of the isoxazoline compositions for the treatment or prophylaxis of parasitic infections and infestations of animals (either wild or domesticated), including livestock and companion animals such as cats, dogs, horses, chickens, sheep, goats, pigs, turkeys and cattle, with the aim of g these hosts of parasites commonly encountered by such animals.

In a particularly preferred embodiment, the composition is a topical n formulation.

In another preferred embodiment particularly well suited for livestock animals, the composition is a l pour-on formulation. The invention also includes other topical compositions comprising an isoxazoline active agent including sprays, aerosols, foams and the like.

In some embodiments, the topical veterinary ition comprises a pharmaceutically acceptable r wherein the carrier comprises a diester of a dicarboxylic acid, a glycol ester, a glycol ether, a fatty acid ester, a polyethylene glycol, or polyethylene glycol ester, an oil, an alcohol, a ol ester, a glycerol ether, propylene glycol, ethylene glycol, a glycol carbonate, dimethyl isosorbide, N-methylpyrrolidone, or a mixture thereof.

In one embodiment, the diester of a dicarboxylic acid is a r of a C6-C16 oxylic acid including, but not limited to, diethyl sebacate or diisopropyl adipate.

In another embodiment of the invention, the pharmaceutically acceptable r of the compositions comprises mixture of a diester of a dicarboxylic acid and a propylene glycol ester, a fatty acid ester, a polyethylene glycol ester, a polyethylene glycol, an oil, a C6-C20 long-chain WO 39948 MER ll-l79PCT aliphatic alcohol, a C1-C8 alcohol, glycol ether, or a combination thereof In certain embodiments, the pharmaceutically acceptable carrier of the topical veterinary composition of the invention further comprises a mixed ester of sucrose and acetic and isobutyric acid, a low melting wax, a hard fat or a block co-polymer of ethylene oxide and propylene oxide, or a combination thereof.

In another embodiment, the pharmaceutically acceptable carrier comprises dimethyl isosorbide, glycerol formal, propylene carbonate, triacetin, diethyleneglycol monoethyl ether, polyethylene glycol 400 or benzyl alcohol, or a mixture f.

The invention also provides methods for the treatment or prevention of tic infections and infestations in animals, comprising administering an effective amount of a composition comprising at least one isoxazoline to the animal. Surprisingly, it has been found that the inventive compositions and formulations bed herein exhibit superior broad um efficacy against harmful ectoparasites more rapidly, and over a long duration compared to compositions known in the art.

In one ment, the invention provides topical veterinary compositions comprising effective amounts of at least one isoxazoline of formula (I) below, in combination and a pharmaceutically or veterinarily acceptable liquid carrier, where variables A1, A2, A3, A4, A5, A6, B1, B2, B3, R1, R2, R3, R4, R5, w are defined .

O—N A \A4 In some embodiments, the l veterinary itions and s comprise 4-[5- [3-chloro(trifluoromethyl)phenyl]-4,5-dihydro(trifluoromethyl)isoxazolyl]-N-[2-oxo- 2,2-trifluoroethyl)amino]ethyl]-l-naphthalenecarboxamide as the active agent.

In other embodiments, the compositions may further comprise one or more additional active agents. In one embodiment, the compositions comprise at least one macrocyclic lactone active agent, ing, but not limited to, avermectins or milbemycins. In some embodiments, MER ll-l79PCT the avermectin or milbemycin active agent is eprinomectin, ivermectin, selamectin, milbemectin, milbemycin D, milbemycin oxime, or moxidectin.

In another embodiment, the topical compositions of the invention e a ation of an isoxazoline active agent with the neonicotinoid active agent nitenpyram.

In other embodiments, the compositions and methods of the invention may fiarther se an insect growth regulator (IGR) active agent, including but not limited to, rene, pyriproxyfen, hydroprene, cyromazine, fluazuron, lufenuron, or novaluron. In another preferred embodiment, the compositions of the invention comprise a neonicotinoid active agent such as nitenpyram. In other embodiments, the compositions and s comprise at least one of ndazole, oxibendazole, mebendazole, fenbendazole, azole, albendazole, triclabendazole, febantel, levamisole, pyrantel, morantel, praziquantel, closantel, clorsulon, an amino acetonitrile active agent, or an zol-2—yl cyanoethylamino active agent.

It is an object of the invention to not encompass within the invention any usly known product, process of making the product, or method of using the product such that the Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method. It is further noted that the ion does not intend to encompass within the scope of the invention any product, process, or making of the t or method of using the product, which does not meet the written description and enablement requirements of the USPTO (35 U.S.C. §llZ, first paragraph) or the EPO (Article 83 of the EPC), such that Applicants reserve the right and hereby disclose a disclaimer of any previously described product, process of making the product, or method of using the product.

These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.

BRIEF DESCRIPTION OF THE DRAWINGS Fig. l is a plot showing the long lasting efficacy of a spot-on composition comprising Compound A against Ctenocephalz’desfelz’s fleas in cats (Example 9).

Fig. 2 is a plot g the long lasting efficacy of a pour-on composition comprising Compound A against Rhipz'cephalus ilus) microplus in cattle based on the number of ticks dropped (Example 15).

MER ll-l79PCT Fig. 3 is a plot showing the long lasting efficacy of a n composition comprising Compound A against ha’pz’cephalus (Boophilus) microplus in cattle based on the weight of ticks that drop le 15).

DETAILED DESCRIPTION The present invention provides novel and inventive topical compositions comprising at least one isoxazoline compound together with a ceutically acceptable carrier or diluent that is suitable for topical application to an animal.

In some embodiments of the invention, the compositions preferably include spot-on or n formulations that are d to a localized area on an animal. Topical spray, aerosol or foam formulations, which typically include the active agent in lower trations, are also encompassed by the invention. These formulations provide surprisingly effective protection of the animals against parasites for an extended period of time. The formulations also provide ely rapid g of parasites infesting animals.

Also provided are methods and uses for the treatment and/or prophylaxis of parasitic infections and infestations of animals, comprising administering an effective amount of a formulation of the invention to the animal.

The ion includes at least the following features: (a) topical veterinary formulations that exhibit superior activity against animal parasites comprising at least one isoxazoline active agent together with a pharmaceutically acceptable carrier or diluent that is suitable for topical application to an animal; (b) topical veterinary compositions that exhibit superior long lasting efficacy that comprise at least one oline compound of formula (I) described herein together with a pharmaceutically acceptable r or diluent that is suitable for topical application to an animal; (c) l veterinary compositions that exhibit or long lasting efficacy that comprise at least one isoxazoline active agent in combination with one or more other active agents together with a pharmaceutically acceptable carrier or diluent that is suitable for topical application to an animal; (d) topical veterinary itions comprising an effective amount of an isoxazoline active agent together with a pharmaceutically able carrier or diluent that is suitable for MER ll-l79PCT topical application to an animal, wherein the carrier does not comprise glycofurol; (e) topical veterinary compositions comprising an effective amount of an isoxazoline active agent together with a pharmaceutically acceptable carrier or diluent that is suitable for topical application to an animal, n the carrier is not a binary e of propylene glycol and glycerol formal; (f) methods for the ent or prevention of parasitic infections and infestations in an animal comprising administering an effective amount of a composition comprising at least one oline active agent together with a pharmaceutically acceptable carrier or diluent; (g) methods for the ent or prevention of parasitic infections and infestations in an animal comprising administering an effective amount of a ition comprising at least one isoxazoline active agent with a pharmaceutically acceptable carrier or diluent that is suitable for topical application to an animal; (h) methods for the ent or prevention of tic infections and infestations in an animal comprising administering an ive amount of a topical ition comprising at least one isoxazoline active agent in combination with one or more other active agents together with a ceutically acceptable carrier or diluent that is suitable for topical application to an animal; (i) use of veterinary compositions comprising at least one isoxazoline nd, including a compound of formula (I), together with a pharmaceutically acceptable r or diluent in the prevention or treatment of animal tes.

In this disclosure and in the claims, terms such “comprises, 3, (C as comprising,” “containing” and “having” and the like can have the meaning ascribed to them in US. Patent law and can mean “includes,” “including,” and the like; “consisting essentially of” or “consists essentially” likewise has the meaning ascribed in US. Patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited is not changed by the presence of more than that which is recited, but excludes prior art embodiments.

Definitions Terms used herein will have their customary meaning in the art unless specified otherwise. The c moieties mentioned in the definitions of the variables of formula (I) are - like the term halogen — collective terms for individual listings of the individual group members.

MER ll-l79PCT The prefix Cn-Cm indicates in each case the possible number of carbon atoms in the group.

The term “animal” is used herein to include all mammals, birds and fish and also include all vertebrate animals. Animals include, but are not limited to, cats, dogs, cattle, chickens, cows, deer, goats, horses, llamas, pigs, sheep and yaks. It also includes an individual animal in all stages of pment, including nic and fetal stages. In some embodiments, the animal will be a non-human animal.

The term “fatty acid” refers to carboxylic acids having from 4 to 26 carbon atoms.

The terms “fatty alcohol” or “long-chain aliphatic alcohol” refer to aliphatic alcohols containing from 6 to 20 carbon atoms.

The term “low g” refers to substances that are solids at room temperature but melt into liquids below 50° C.

The term “alkyl” refers to saturated straight, branched, cyclic, primary, secondary or tertiary arbons, including those having 1 to 20 atoms. In some embodiments, alkyl groups will include C1-C12, C1-C10, C1-C8, C1-C6 or C1-C4 alkyl groups. Examples of C1-C10 alkyl include, but are not limited to, methyl, ethyl, propyl, l-methylethyl, butyl, l-methylpropyl, 2- methylpropyl, l,l-dimethylethyl, , l-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2- dimethylpropyl, l-ethylpropyl, hexyl, l,l-dimethylpropyl, l,2-dimethylpropyl, l-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, l,l-dimethylbutyl, l,2-dimethylbutyl, 1,3- dimethylbutyl, methylbutyl, methylbutyl, 3,3-dimethylbutyl, lbutyl, 2- utyl, l,l,2-trimethylpropyl, l,2,2-trimethylpropyl, l-l-methylpropyl, l-ethyl methylpropyl, heptyl, octyl, 2-ethylhexyl, nonyl and decyl and their isomers. C1-C4-alkyl means for example methyl, ethyl, propyl, l-methylethyl, butyl, l-methylpropyl, 2-methylpropyl or l,l- dimethylethyl.

Cyclic alkyl groups or “cycloalkyl”, which are encompassed by alkyl include those with 3 to 10 carbon atoms having single or multiple sed rings. In some embodiments, cycloalkyl groups include C4-C7 or C3-C4 cyclic alkyl groups. Non-limiting examples of cycloalkyl groups include adamantyl, ropyl, cyclobutyl, cyclopentyl, exyl, cycloheptyl, cyclooctyl and the like.

The alkyl groups described herein can be unsubstituted or substituted with one or more moieties selected from the group consisting of alkyl, halo, haloalkyl, hydroxyl, carboxyl, acyl, acyloxy, amino, alkyl- or dialkylamino, amido, arylamino, alkoxy, aryloxy, nitro, cyano, azido, 2012/054719 MER ll-l79PCT thiol, imino, sulfonic acid, sulfate, sulfonyl, sulfanyl, yl, sulfamonyl, ester, phosphonyl, phosphinyl, phosphoryl, phosphine, thioester, thioether, acid halide, anhydride, oxime, hydrazine, carbamate, oric acid, phosphate, phosphonate, or any other viable fianctional group that does not inhibit the biological activity of the nds of the invention, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Third Edition, 1999, hereby incorporated by reference.

Terms including the term “alkyl” such as “alkylcycloalkyl,” “cycloalkylalkyl,” “alkylamino,” or “dialkylamino” will be understood to se an alkyl group as defined above linked to the other functional group, where the group is linked to the compound through the last group listed, as understood by those of skill in the art.

The term “alkenyl” refers to both straight and branched carbon chains which have at least one carbon-carbon double bond. In some embodiments, alkenyl groups may e C2-C20 alkenyl groups. In other embodiments, alkenyl includes C2-C12, C2-C10, C2-C8, C2-C6 or C2-C4 alkenyl groups. In one embodiment of alkenyl, the number of double bonds is l-3, in another embodiment of alkenyl, the number of double bonds is one or two. Other ranges of - carbon double bonds and carbon numbers are also contemplated depending on the location of the alkenyl moiety on the le. “C2-C10-alkenyl” groups may include more than one double bond in the chain. Examples include, but are not limited to, ethenyl, l-propenyl, 2-propenyl, l- methyl-ethenyl, l-butenyl, 2-butenyl, nyl, l-methyl-l-propenyl, 2-methyl-l-propenyl, l- methylpropenyl, 2-methylpropenyl; l-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, l- methyl-l-butenyl, 2-methyl-l-butenyl, 3-methyl-l-butenyl, l-methylbutenyl, 2-methyl butenyl, 3-methylbutenyl, l-methylbutenyl, 2-methylbutenyl, 3-methylbutenyl, l,l- ylpropenyl, l,2-dimethyl-l-propenyl, l,2-dimethylpropenyl, l-ethyl-l-propenyl, l- ethylpropenyl, l-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, l-methyl-l-pentenyl, 2-methyl-l-pentenyl, 3-methyl-l-pentenyl, 4-methyl-l-pentenyl, l-methylpentenyl, 2-methyl- 2-pentenyl, 3-methylpentenyl, ylpentenyl, ylpentenyl, yl pentenyl, 3-methylpentenyl, 4-methylpentenyl, l-methylpentenyl, ylpentenyl, 3-methylpentenyl, 4-methylpentenyl, l,l-dimethylbutenyl, l,l-dimethylbutenyl, l,2- dimethyl-l-butenyl, l,2-dimethylbutenyl, l,2-dimethylbutenyl, l,3-dimethyl-l-butenyl, l,3-dimethylbutenyl, l,3-dimethylbutenyl, 2,2-dimethylbutenyl, 2,3-dimethyl-l-butenyl, MER ll-l79PCT 2,3-dimethylbutenyl, 2,3-dimethylbutenyl, 3,3-dimethyl-l-butenyl, 3,3-dimethylbutenyl, l-ethyl-l-butenyl, l-ethylbutenyl, l-ethylbutenyl, l-l-butenyl, 2-ethylbutenyl, 2- ethylbutenyl, l,l,2-trimethylpropenyl, l-ethyl-l-methylpropenyl, l-ethylmethyl-lpropenyl and l-ethylmethylpropenyl.

“Alkynyl” refers to both straight and branched carbon chains which have at least one carbon-carbon triple bond. In one embodiment of l, the number of triple bonds is l-3; in another embodiment of l, the number of triple bonds is one or two. In some embodiments, alkynyl groups include from C2-C20 alkynyl groups. In other embodiments, alkynyl groups may e C2-C12, C2-C10, C2-C8, C2-C6 or C2-C4 l groups. Other ranges of carbon-carbon triple bonds and carbon numbers are also contemplated depending on the location of the alkenyl moiety on the molecule. For example, the term ”C2-C10-alkynyl” as used herein refers to a straight-chain or branched unsaturated hydrocarbon group haVing 2 to 10 carbon atoms and containing at least one triple bond, such as ethynyl, -yn-l-yl, propyn-l-yl, n-but-l-yn- l-yl, n-but-l-ynyl, l-ynyl, n-butyn-l-yl, n-pent-l-yn-l-yl, n-pent-l-ynyl, n- pent-l-ynyl, n-pent-l-yn-S-yl, n-pentyn-l-yl, n-pentynyl, n-pentynyl, 3- methylbut-l-ynyl, 3-methylbut-l-ynyl, l-yn-l-yl, n-heX-l-ynyl, n-heX-l-ynyl, n-heX-l-yn-S-yl, n-heX-l-ynyl, n-heXyn-l-yl, n-heXynyl, n-heXynyl, n-hex ynyl, n-heXyn-l-yl, n-heXynyl, 3-methylpent-l-yn-l-yl, 3-methylpent-l-ynyl, 3- methylpent-l-ynyl, 3-methylpent-l-ynyl, 4-methylpent-l-yn-l-yl, 4-methylpentynyl or 4-methylpentynyl and the like.

The term “haloalkyl” refers to an alkyl group, as defined herein, Which is substituted by one or more n atoms. For example C1-C4-haloalkyl includes, but is not limited to, chloromethyl, bromomethyl, dichloromethyl, oromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, l-chloroethyl, l-bromoethyl, l-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichlorofluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl and the like.

The term lkenyl” refers to an l group, as defined herein, Which is substituted by one or more halogen atoms.

The term “haloalkynyl” refers to an alkynyl group, as defined herein, Which is tuted by one or more halogen atoms.

MER ll-l79PCT “Alkoxy” refers to alkyl-O-, wherein alkyl is as defined above. Similarly, the terms “alkenyloxy, 3, (6alkynyloxy,” “haloalkoxy,” “haloalkenyloxy,” “haloalkynyloxy,3, oalkoxy,” “cycloalkenyloxy,” “halocycloalkoxy,” and “halocycloalkenyloxy” refer to the groups alkenyl- O-, alkynyl-O-, haloalkyl-O-, haloalkenyl-O-, haloalkynyl-O-, cycloalkyl-O-, cycloalkenyl-O-, halocycloalkyl-O-, and cloalkenyl-O-, respectively, wherein l, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkenyl, halocycloalkyl, and halocycloalkenyl are as defined above. Examples of C1-C6-alkoxy include, but are not limited to, methoxy, ethoxy, Csz-CHzO-, (CH3)2CHO-, n-butoxy, Csz-CH(CH3)O-, (CH3)2CH-CHgO-, (CH3)3CO-, n- pentoxy, l lbutoxy, 2-methylbutoxy, 3 -methylbutoxy, l l -dimethylpropoxy, l,2-dimethylpropoxy, 2,2-dimethyl-propoxy, l-ethylpropoxy, n-hexoxy, l-methylpentoxy, 2- methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, l,l-dimethylbutoxy, l,2-dimethylbutoxy, methylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, l- ethylbutoxy, 2-ethylbutoxy, l,l,2-trimethylpropoxy, l,2,2-trimethylpropoxy, l-ethyl-l- methylpropoxy, l-ethylmethylpropoxy and the like.

The term “alkylthio” refers to alkyl-S-, wherein alkyl is as defined above. Similarly, the terms lkylthio, 3, (6cycloalkylthio,” and the like, refer to haloalkyl-S- and cycloalkyl-S- where haloalkyl and cycloalkyl are as defined above.

The term “alkylsulfinyl” refers to alkyl-S(O)-, wherein alkyl is as defined above.

Similarly, the term “haloalkylsulfinyl” refers to haloalkyl-S(O)- where haloalkyl is as defined above.

The term “alkylsulfonyl” refers to alkyl-S(O)2-, wherein alkyl is as defined above.

Similarly, the term “haloalkylsulfonyl” refers to haloalkyl-S(O)2- where haloalkyl is as defined above.

The term alkylamino and dialkylamino refer to alkyl-NH- and (alkyl)2N- where alkyl is as defined above. Similarly, the terms “haloalkylamino” refers to haloalkyl-NH- where haloalkyl is as defined above.

The terms “alkylcarbonyl,” ycarbonyl,” aminocarbonyl,” and ylaminocarbonyl” refer to alkyl-C(O)—, alkoxy-C(O)—, alkylamino-C(O)- and lamino-C(O)— where alkyl, alkoxy, alkylamino and lamino are as defined above.

Similarly, the terms “haloalkylcarbonyl,” lkoxycarbonyl,” "haloalkylaminocarbonyl," and "dihaloalkylaminocarbonyl" refer to the groups haloalkyl-C(O)-, haloalkoxy-C(O)-, WO 39948 MER ll-l79PCT haloalkylamino-C(O)- and dihaloalkylamino-C(O)- Where haloalkyl, haloalkoxy, haloalkylamino and dihaloalkylamino are as defined above.

“Aryl” refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring or multiple condensed rings. In some embodiments, aryl groups include C6- C10 aryl groups. Aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, tetrahydronaphtyl, phenylcyclopropyl and indanyl. Aryl groups may be unsubstituted or substituted by one or more es ed from halogen, cyano, nitro, hydroxy, mercapto, amino, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, kyl, haloalkenyl, haloalkynyl, halocycloalkyl, halocycloalkenyl, alkoxy, alkenyloxy, alkynyloxy, haloalkoxy, haloalkenyloxy, haloalkynyloxy, lkoxy, lkenyloxy, halocycloalkoxy, halocycloalkenyloxy, alkylthio, haloalkylthio, cycloalkylthio, halocycloalkylthio, alkylsulfinyl, alkenylsulfinyl, alkynyl-sulfinyl, haloalkylsulfinyl, haloalkenylsulfinyl, haloalkynylsulfinyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, haloalkyl-sulfonyl, haloalkenylsulfonyl, kynylsulfonyl, alkylamino, alkenylamino, alkynylamino, di(alkyl)amino, di(alkenyl)-amino, di(alkynyl)amino, or ylsilyl.

The terms “aralkyl” or “arylalkyl” refers to an aryl group that is bonded to the parent compound through a diradical alkylene bridge, )n, Where n is l-l2 and Where “aryl” is as defined above.

“Heteroaryl” refers to a monovalent aromatic group of from 1 to 15 carbon atoms, preferably from 1 to 10 carbon atoms, having one or more oxygen, nitrogen, and sulfur heteroatoms Within the ring, preferably 1 to 4 heteroatoms, or 1 to 3 heteroatoms. The nitrogen and sulfur heteroatoms may optionally be oxidized. Such aryl groups can have a single ring (e. g., pyridyl or furyl) or multiple condensed rings provided that the point of attachment is through a heteroaryl ring atom. Preferred heteroaryls include pyridyl, piridazinyl, pyrimidinyl, pyrazinyl, triazinyl, pyrrolyl, indolyl, quinolinyl, isoquinolinyl, olinyl, quinoxalinnyl, furanyl, thiophenyl, filryl, pyrrolyl, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyrazolyl benzofuranyl, and benzothiophenyl. aryl rings may be unsubstituted or substituted by one or more moieties as described for aryl above.

“Heterocyclyl,” “heterocyclic” or “heterocyclo” refer to fully saturated or unsaturated, cyclic , for example, 3 to 7 membered monocyclic or 4 to 7 membered monocyclic; 7 to ll membered ic, or 10 to 15 membered tricyclic ring systems, which have one or more MER ll-l79PCT oxygen, sulfur or nitrogen heteroatoms in ring, preferably 1 to 4 or 1 to 3 heteroatoms. The nitrogen and sulfur heteroatoms may ally be oxidized and the nitrogen heteroatoms may optionally be quaternized. The heterocyclic group may be attached at any heteroatom or carbon atom of the ring or ring system and may be unsubstituted or substituted by one or more moieties as described for aryl groups above.

Exemplary monocyclic heterocyclic groups include, but are not limited to, pyrrolidinyl, yl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, olinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, filryl, tetrahydrofuryl, thienyl, zolyl, dinyl, piperazinyl, 2- oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, pyridinyl, nyl, pyrimidinyl, pyridazinyl, tetrahydropyranyl, morpholinyl, rpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, l,3-dioxolane and tetrahydro-l,ldioxothienyl , lyl, triazinyl, and the like.

Exemplary bicyclic heterocyclic groups include, but are not limited to, l, benzothiazolyl, benzoxazolyl, benzodioxolyl, benzothienyl, quinuclidinyl, quinolinyl, tetra- hydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, opyridyl, furopyridinyl (such as ,3-c]pyridinyl, fiaro[3,2-b]pyridinyl]or filro[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as hydrooxo-quinazolinyl), tetrahydroquinolinyl and the like.

Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, nyl, phenanthridinyl, xanthenyl, and the like.

Halogen means the atoms fluorine, chlorine, bromine and iodine. The designation of “halo” (e.g. as illustrated in the term haloalkyl) refers to all degrees of substitutions from a single substitution to a perhalo substitution (e.g. as illustrated with methyl as chloromethyl (-CH2Cl), dichloromethyl (-CHC12), trichloromethyl (-CC13)).

Stereoisomers and polymorphic forms It will be appreciated by those of skill in the art that certain compounds Within the compositions of the invention may exist and be isolated as optically active and racemic forms. nds haVing one or more chiral centers, including at a sulfur atom, may be present as single enantiomers or diastereomers or as mixtures of enantiomers and/or diastereomers. For MER ll-l79PCT example, it is well known in the art that sulfoxide nds may be optically active and may exist as single omers or racemic mixtures. In addition, compounds within the compositions of the invention may include one or more chiral centers, which results in a theoretical number of optically active isomers. Where compounds within the compositions of the invention include 11 chiral centers, the compounds may se up to 211 optical isomers. The present ion encompasses the specific enantiomers or diastereomers of each compound as well as mixtures of different enantiomers and/or diastereomers of the compounds of the invention that possess the useful ties described herein. The optically active forms can be prepared by, for example, resolution of the racemic forms by selective crystallization techniques, by synthesis from optically active precursors, by chiral synthesis, by chromatographic tion using a chiral stationary phase or by enzymatic resolution.

The compounds within the compositions of present invention may also be present in different solid forms such as different crystalline forms or in the form of an amorphous solid.

The present invention encompasses different crystalline forms as well as amorphous forms of the ive compounds.

In addition, the nds within the compositions of the invention may exist as hydrates or solvates, in which a certain stoichiometric amount of water or a solvent is associated with the molecule in the crystalline form. The compositions of the invention may include hydrates and solvates of the active agents. In some embodiments, the compositions of the invention may include up to 15% (w/w), up to 20% (w/w), or up to 30% (w/w) of a particular solid form.

Salts Also contemplated within the scope of the invention are acid or base salts, where applicable, of the compounds of the invention provided for herein.

The term "acid salt" contemplates salts of the compounds with all pharmaceutically acceptable inorganic or organic acids. Inorganic acids e mineral acids such as hydrohalic acids such as hydrobromic acid and hydrochloric acid, sulfuric acid, phosphoric acids and nitric acid. Organic acids e all ceutically acceptable aliphatic, alicyclic and aromatic carboxylic acids, oxylic acids, tricarboxylic acids and fatty acids. In one embodiment of the acids, the acids are straight chain or branched, saturated or rated C1-C20 aliphatic carboxylic acids, which are optionally substituted by halogen or by hydroxyl groups, or C6-C12 2012/054719 MER ll-l79PCT aromatic carboxylic acids. Examples of such acids are carbonic acid, formic acid, acetic acid, propionic acid, pionic acid, valeric acid, a-hydroxy acids such as glycolic acid and lactic acid, chloroacetic acid, benzoic acid, methane ic acid, and salicylic acid. Examples of dicarboxylic acids include oxalic acid, malic acid, succinic acid, tartaric acid, fumaric acid, and maleic acid. An example of a boxylic acid is citric acid. Fatty acids include all pharmaceutically acceptable ted or rated aliphatic or ic carboxylic acids having 4 to 24 carbon atoms. Examples include butyric acid, isobutyric acid, sec-butyric acid, lauric acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and phenylsteric acid. Other acids include gluconic acid, glycoheptonic acid and lactobionic acid.

The term “base salt” contemplates salts of the compounds with all pharmaceutically acceptable inorganic or organic bases, including hydroxides, carbonates or bicarbonates of alkali metal or alkaline earth metals. Salts formed with such bases include, for example, the alkali metal and alkaline earth metal salts, including, but not limited to, as the lithium, sodium, potassium, magnesium or calcium salts. Salts formed with organic bases include the common hydrocarbon and heterocyclic amine salts, which include, for example, ammonium salts (NH4+), alkyl- and dialkylammonium salts, and salts of cyclic amines such as the morpholine and piperidine salts.

In one embodiment, the invention es topical veterinary compositions comprising effective amounts of at least one isoxazoline of formula (1) below, in combination and a pharmaceutically or veterinarily able liquid carrier: O—N A6” \A4 wherein A1, A2, A3, A4, A5 and A6 are independently CR3 or N, provided that at most 3 of A1, A2, A3, A4, A5 and A6 are N; B1, B2 and B3 are independently CR2 or N; MER ll-l79PCT W is O or S; R1 is alkyl, alkenyl, l, cycloalkyl, alkylcycloalkyl or cycloalkylalkyl, each optionally substituted with one or more tuents independently selected from R6; each R2 is independently H, halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, hio, haloalkylthio, alkylsulfinyl, kylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, niino, dialkylaniino, alkoxycarbonyl, —CN or —N02; each R3 is independently H, n, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylaniino, dialkylarnino, —CN or —N02; R4 is H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, alkylcarbonyl or alkoxycarbonyl; R5 is H, ORIO, NRUR12 or Q1; or alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl or cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R7; or R4 and R5 are taken er with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom ed from the group consisting of N, S and 0, said ring optionally substituted with l to 4 substituents independently selected from the group consisting of alkyl, halogen, —CN, —N02 and alkoxy; each R6 is independently halogen, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, —CN or —N02; each R7 is independently halogen; alkyl, lkyl, , alkylthio, alkylsulfinyl, alkylsulfonyl, niino, dialkylaniino, cycloalkylaniino, alkylcarbonyl, alkoxycarbonyl, alkylaniinocarbonyl, dialkylaniinocarbonyl, haloalkylcarbonyl, haloalkoxycarbonyl, haloalkylaniinocarbonyl, dihaloalkylarninocarbonyl, hydroxy, —NH2, —CN or —N02; or Q2; each R8 is independently halogen, alkoxy, koxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylaniino, dialkylaniino, alkoxycarbonyl, —CN or —N02; each R9 is independently halogen, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, alkylsulfinyl, haloalkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, alkylaniino, dialkylaniino, —CN, —N02, phenyl or pyridinyl; MER ll-l79PCT R10 is H; or alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl or cycloalkylalkyl, each optionally substituted with one of more halogen; R“ is H, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, alkylcarbonyl or alkoxycarbonyl; R12 is H; Q3; or alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl or cycloalkylalkyl, each optionally tuted with one or more tuents independently selected from R7; or R11 and R12 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and 0, said ring optionally substituted with l to 4 substituents independently selected from the group consisting of alkyl, n, —CN, —N02 and alkoxy; Q1 is a phenyl ring, a 5- or 6-membered heterocyclic ring, or an 8-, 9- or 10- membered fused bicyclic ring system optionally containing one to three heteroatoms selected from up to l 0, up to l S and up to 3 N, each ring or ring system optionally tuted with one or more substituents independently selected from R8; each Q2 is independently a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally tuted with one or more substituents independently ed from R9; Q3 is a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from R9; and n is 0, l or 2.

In one embodiment, the invention provides topical veterinary compositions sing effective amounts of at least one isoxazoline of formula (1) below, in combination and a pharmaceutically or narily acceptable liquid carrier: wherein: 2012/054719 MER ll-l79PCT A1, A2, A3, A4, A5 and A6 are independently CR3 or N, provided that at most 3 of A1, A2, A3, A4, A5 and A6 are N; B1, B2 and B3 are independently CR2 or N; W is O or S; R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R6; each R2 is ndently H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylaniino, C2-C6 dialkylaniino, C2-C4 alkoxycarbonyl, —CN or —N02; each R3 is independently H, halogen, C1-C6 alkyl, C1-C6 kyl, C3-C6 cycloalkyl, C3- C6 halocycloalkyl, C1- C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1- C6 ulfinyl, C1-C6 kylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 kylsulfonyl, C1-C6 alkylaniino, C2-C6 dialkylaniino, —CN or —N02; R4 is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C4-C7 cycloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl; R5 is H, ORIO, NRUR12 or Q1; or C1-C6 alkyl, C2-C6 l, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 lkylalkyl, each optionally substituted with one or more substituents independently selected from R7; or R4 and R5 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and 0, said ring optionally substituted with l to 4 substituents independently selected from the group consisting of C1-C2 alkyl, halogen, —CN, —N02 and C1-C2 alkoxy; each R6 is independently halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, —CN or —N02; each R7 is independently halogen; C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 alkylaniino, C2-C8 dialkylaniino, C3- C6 cycloalkylaniino, C2-C7 alkylcarbonyl, C2-C7 alkoxycarbonyl, C2-C7 alkylaniinocarbonyl, C3-C9 laminocarbonyl, C2-C7 haloalkylcarbonyl, C2-C7 haloalkoxycarbonyl, C2-C7 MER PCT haloalkylaminocarbonyl, C3-C9 dihaloalkylaminocarbonyl, y, —NH2, —CN or —N02; or Q2; each R8 is independently n, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1- C6 haloalkylthio, C1- C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 ulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, C2-C4 alkoxycarbonyl, —CN or — N02; each R9 is independently halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 lkyl, C3-C6 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1- C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, C1-C6 alkylamino, C2-C6 dialkylamino, —CN, —N02, phenyl or pyridinyl; R10 is H; or C1-C6 alkyl, C2-C6 l, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each ally substituted with one of more halogen; R“ is H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl, C4-C7 cycloalkylalkyl, C2-C7 alkylcarbonyl or C2-C7 alkoxycarbonyl; R12 is H; Q3; or C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R7; or R11 and R12 are taken together with the nitrogen to which they are attached to form a ring containing 2 to 6 atoms of carbon and optionally one additional atom selected from the group consisting of N, S and 0, said ring optionally tuted with l to 4 substituents independently selected from the group ting of C1-C2 alkyl, halogen, —CN, —N02 and C1-C2 alkoxy; Q1 is a phenyl ring, a 5- or 6-membered heterocyclic ring, or an 8-, 9- or 10- membered fused bicyclic ring system optionally containing one to three atoms selected from up to l 0, up to l S and up to 3 N, each ring or ring system optionally substituted with one or more substituents independently selected from R8; each Q2 is independently a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from R9; Q3 is a phenyl ring or a 5- or 6-membered heterocyclic ring, each ring optionally substituted with one or more substituents independently selected from R9; and nis0,lor2.

MER ll-l79PCT In one embodiment of formula (I), W is O. In another embodiment, W is S.

In another embodiment of formula (I), A1, A2, A3, A4, A5 and A6 are each CR3.

In another embodiment of formula (I), B1, B2 and B3 are each CR2.

In still r embodiment of formula (I), W is O and A1, A2, A3, A4, A5 and A6 are each CR3.

In yet another ment of formula (I), W is 0; A1, A2, A3, A4, A5 and A6 are each CR3; and B1, B2 and B3 are each CR2.

In another embodiment of formula (I), A1, A2, A3, A4, A5 and A6 are each CH.

In another embodiment of formula (I), B1, B2 and B3 are each CR2; and R2 is H, halogen, C1-C6 alkyl or C1-C6 haloalkyl.

In still another embodiment of formula (I), R1 is C1-C3 alkyl optionally substituted by one or more of R6; R2 is independently H, halogen, C1-C6 haloalkyl, C1-C6 haloalkoxy or —CN; and each R3 is independently H, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, C3-C6 halocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, -CN or —N02.

In still another ment, the invention provides a composition comprising an isoxazoline of formula (I) wherein: W is O or S; R4 is H or C1-C6 alkyl; R5 is —CH2C(O)NHCH2CF3; each of A1=A2=A3=A4=A5=A6 is CH; R1 is C1-C6 alkyl each optionally tuted with one or more substituents independently selected from R6; R6 is halogen or C1-C6 alkyl; and B1 and B3 are independently CH, C-halogen, C-Cl-C6 alkyl, C-Cl-C6 haloalkyl, or C- , B2, C1-C6 alkoxy.

In r embodiment of formula (I), B1, B2 and B3 are independently CR2; W is O; R4 is H, C1-C6 alkyl, C2-C7 alkylcarbonyl or C2-C7 carbonyl; and R5 is H, NRUR12 or Q1; or C1-C4 alkyl, C2-C4 alkenyl, C2-C4 l, C3-C4 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more of R7. 2012/054719 MER ll-l79PCT In still another embodiment of formula (I), R1 is C1-C3 alkyl ally tuted with halogen; each R2 is independently H, CF3, OCFg, halogen or —CN; each R3 is independently H, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C1-C4 alkoxy or —CN; and each R7 is independently halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C2-C4 alkylcarbonyl, C2-C4 alkoxycarbonyl, C2-C5 alkylaminocarbonyl, C2-C5 haloalkylcarbonyl, C2-C5 haloalkoxycarbonyl, C2-C5 haloalkylaminocarbonyl, -NH2, -CN or N02; or Q2.

In yet another embodiment of formula (I), R4 is H; R5 is C1-C4 alkyl optionally substituted with one or more R7; each R7 is independently halogen or Q2; and each Q2 is independently phenyl, pyridinyl or thiazolyl.

In still another embodiment of formula (I), R1 is CF3; A1, A2, A3, A4, A5 and A6 are each CR3; B2 is CR2; and each R3 is ndently H, C1-C4 alkyl or —CN.

In another embodiment, B2 is CH; B1 and B3 are each CR2 where each R2 is independently n or C1-C3 haloalkyl; A1, A2, A3, A4, A5 and A6 are each CR3; R3 is H; and n is 2.

In still another embodiment of formula (I), R1 is CF3; A1, A2, A3, A4, A5 and A6 are each CR3; 13.2 is CH; each of B1 and B3 are CR2; each R3 is independently H or C1-C4 alkyl; each R2 is independently halogen or C1-C3 haloalkyl; R4 is H; R5 is C1-C4 alkyl optionally substituted with one or more R7; and MER ll-l79PCT R7 is C2-C7 arbonyl, C2-C7 alkoxycarbonyl, C2-C7 alkylaminocarbonyl, C3-C9 dialkylaminocarbonyl, C2-C7 haloalkylcarbonyl, C2-C7 haloalkoxycarbonyl, C2-C7 haloalkylaminocarbonyl, C3-C9 dihaloalkylaminocarbonyl.

In yet r embodiment of formula (I), R1 is CF3; A1, A2, A3, A4, A5 and A6 are each CH; 13.2 is CH; each of B1 and B3 are CR2; each R2 is independently halogen or C1-C3 haloalkyl; R4 is H; R5 is C1-C4 alkyl optionally substituted with one or more R7; and R7 is C2-C7 alkylaminocarbonyl, C3-C9 dialkylaminocarbonyl, C2-C7 haloalkylaminocarbonyl or C3-C9 dihaloalkylaminocarbonyl.

In a preferred embodiment, a topical composition comprising an isoxazoline active agent of formula (I) is provided, wherein: R1 is C133; W is 0; A1, A2, A3, A4, A5 and A6 are each CH; 13.2 is CH; B1 is ; 13.2 is CF3; R4 is H; R5 is CH2C(O)NHCH2CF3; and n is 2.

In a preferred embodiment, the isoxazoline compound is 4-[5-[3-chloro (trifluoromethyl)phenyl]-4,5-dihydro(trifluoromethyl)isoxazolyl]—N—[2-oxo[(2,2,2- trifluoroethyl)amino]ethyl]- l -naphthalanecarboxamide (Compound A).

In another embodiment, the compositions of the ion may include one or more compounds of the isoxazolines disclosed in , WO 2007/075459 and US 2009/0133319, and US 2009/0143410, , , WO 24541, and US 2007/0066617 and , all of which are orated herein by reference in their entirety.

MER 11-179PCT In other red embodiments, the invention provides topical compositions comprising an isoxazoline active agent described in WC 2009/02451A2 and A1, both orated herein by reference in their entirety, in combination with a pharmaceutically acceptable carrier or diluent.

In another preferred ment, the invention provides topical compositions comprising compound 11-1 described in WC 2009/02451A2, which has the structure: {33? in combination with a pharmaceutically acceptable carrier or diluent described herein.

In still r embodiment the invention es topical compositions comprising one or more of the isoxazoline compounds of formulae 1.001 to 1.025 and 2.001 to 2.018 described in WO 2011075591 in combination with a pharmaceutically able carrier described herein: Compound MS RT LCMS No. (2), MH+ (mm) Method 1.001 3,5-C12 582 2.21 1 c-H c-H c-H c-H ——----—--—— 1.005 3,5-(CF3)2 C-H C—H C-H C-H c-H c-H c-H c-H—-—-2.31 c-H c-H c-H c-H c-H 2.18 MER 11-179PCT 1.010 Qm 9m CH2CF3 1.011 0 E O m CH2C(O)NHCH2CF3 581 1.012 CH2CF3 1.013 CHZCHZSCH3 1.014 CH2C(O)NHCH2CF3 1.015 CH2CF3 1.016 CHZCHZSCHg 1.017 CH2C(O)NHCH2CF3 1.018 99mm CHZCF3 1.019 9mm CHZCHZSCH3 __1.020 3,5-(CF3)2 C- 0 CH2C(O)NHCH2CF3 __1.021 3,5-(CF3)2 0 g: CHZCF3 --C1.022 3,5-(CF3)2 —m C—H C-H CHZCHZSCH3 1.023 3—C1,5—CF3 C-H C-Me on R? )NHCH2CF3 __1.024 3—C1,5—CF3 C-H C—H O 23a CH2CF3 __1.025 3—C1,5—CF3 C-H C—H O CHZCHZSCHg Compounds 2.001 to 2.018 Compound MS LCMS N0. 2 B5 B4 B3 B2 B1 R15 R16 MH+ (mm) Method C-H C-H N C-H CH2C(O)NHCH2CF3 C-H C-H N C-H C-H CHZCF3 C-H C-H N C-H C-H CHZCHZSCH3 c-H c-H CH2C(O)NHCH2CF3 650 1.85 1 011—— 2.006 3,5-(CF3)2 C—H C-H N C-H C-H CHZCHZSCH3 2.007 3—C1,5—CF3 C—H C-H N C-H C-H )NHCH2CF3 c-H—— c-H—— c-H——EEEEEEEEEEEE 2.011 2 C-H C-H C-H C-H C-H CH2CF3 2.012 3,5-C12 C-H C-H C-H C-H C-H CHZCHZSCH3 MER ll-l79PCT 3,5-(CF3)2 CH2C(O)NHCH2CF3 2.014 3,5-(CF3)2 C-H C-H C-H CHZCF3 — 2.01s as—mmz c-H c-H CHZCHZSCH. — 2.016 3-C1,5-CF3 C-H C-H CH2C(O)NHCH2CF3— 2.017 3-Cl,5-CF3 C-H C-H C-H C-H C-H CHZCF3 2.018 3-Cl,5-CF3 C-H C-H C-H C-H C-H CHZCHZSCHg In one ment, the invention provides a topical composition comprising at least one oline of formula (I) in combination at least one other active agent, and a pharmaceutically able carrier or diluent.

Additional veterinary/pharmaceutical active ients may be used With the compositions of the invention. In some embodiments, the onal active agents may include, but are not limited to, acaricides, anthelmintics, anti-parasitics and insecticides. Anti-parasitic agents can include both ectoparasiticidal and/or endoparasiticidal agents.

Veterinary pharmaceutical agents that may be ed in the compositions of the invention are well-known in the art (see e. g. Plumb ’ nary Drag Handbook, 5th Edition, ed.

Donald C. Plumb, Blackwell Publishing, (2005) or The Merck Veterinary Manual, 9th Edition, (January 2005)) and include but are not limited to acarbose, acepromazine maleate, acetaminophen, olamide, acetazolamide sodium, acetic acid, acetohydroxamic acid, acetylcysteine, acitretin, acyclovir, albendazole, albuterol sulfate, alfentanil, allopurinol, alprazolam, altrenogest, amantadine, amikacin sulfate, aminocaproic acid, aminopentamide hydrogen e, aminophylline/theophylline, amiodarone, amitriptyline, amlodipine besylate, ammonium chloride, ammonium molybdenate, amoxicillin, clavulanate potassium, amphotericin B desoxycholate, amphotericin B based, ampicillin, amprolium, ds (oral), antivenin, apomorphione, apramycin sulfate, ascorbic acid, asparaginase, aspiring, atenolol, atipamezole, atracurium te, atropine sulfate, aumofin, aurothioglucose, azaperone, azathioprine, azithromycin, baclofen, barbituates, benazepril, betamethasone, bethanechol chloride, bisacodyl, bismuth subsalicylate, bleomycin sulfate, boldenone undecylenate, bromides, bromocriptine mesylate, budenoside, orphine, buspirone, busulfan, butorphanol tartrate, cabergoline, calcitonin salmon, calcitrol, calcium salts, captopril, icillin indanyl sodium, azole, carboplatin, camitine, carprofen, carvedilol, cefadroxil, cefazolin sodium, me, clorsulon, cefoperazone sodium, cefotaXime sodium, cefotetan disodium, cefoxitin sodium, cefpodoxime il, ceftazidime, ceftiofur sodium, ceftiofur, ceftiaxone sodium, cephalexin, cephalosporins, MER ll-l79PCT cephapirin, charcoal (activated), chlorambucil, chloramphenicol, chlordiazepoxide, chlordiazepoxide +/- clidinium bromide, chlorothiazide, heniramine maleate, chlorpromazine, chlorpropamide, chlortetracycline, chorionic gonadotropin (HCG), chromium, cimetidine, ciprofloxacin, cisapride, cisplatin, citrate salts, clarithromycin, clemastine fumarate, clenbuterol, clindamycin, clofazimine, clomipramine, claonazepam, clonidine, cloprostenol sodium, clorazepate dipotassium, clorsulon, cloxacillin, codeine phosphate, colchicine, corticotropin (ACTH), cosyntropin, cyclophosphamide, cyclosporine, cyproheptadine, bine, dacarbazine, dactinomycin/actinomycin D, dalteparin sodium, danazol, dantrolene sodium, dapsone, decoquinate, xamine mesylate, deracoxib, deslorelin acetate, desmopressin acetate, corticosterone pivalate, dine, dexamethasone, dexpanthenol, dexraazoxane, dextran, diazepam, diazoxide (oral), dichlorphenamide, diclofenac sodium, dicloxacillin, lcarbamazine citrate, diethylstilbestrol (DES), difloxacin, digoxin, dihydrotachysterol (DHT), diltiazem, dimenhydrinate, dimercaprol/BAL, dimethyl ide, ost tromethamine, diphenylhydramine, disopyramide phosphate, dobutamine, docusate/DSS, tron mesylate, domperidone, dopamine, doramectin, doxapram, doxepin, doxorubicin, doxycycline, edetate calcium disodium.calcium EDTA, edrophonium chloride, enalapril/enalaprilat, enoxaparin sodium, enrofloxacin, ephedrine sulfate, epinephrine, epoetin/erythropoietin, eprinomectin, epsiprantel, erythromycin, esmolol, estradiol cypionate, ethacrynic acid/ethacrynate sodium, ethanol (alcohol), etidronate sodium, etodolac, ate, euthanasia agents W/pentobarbital, famotidine, fatty acids (essential/omega), felbamate, fentanyl, ferrous sulfate, filgrastim, f1nasteride, f1pronil, icol, fluconazole, flucytosine, fludrocortisone acetate, flumazenil, flumethasone, n meglumine, fluorouracil , fluoxetine, fluticasone propionate, fluvoxamine maleate, fomepizole , furazolidone, furosemide, gabapentin, gemcitabine, gentamicin sulfate, glimepiride, glipizide, glucagon, glucocorticoid , glucosamine/chondroitin sulfate, glutamine, glyburide, ine (oral), glycopyrrolate, gonadorelin, grisseofulVin, guaifenesin, halothane, hemoglobin er—200 (OXYGLOBIN®®), heparin, hetastarch, hyaluronate sodium, hydrazaline, hlorothiazide, hydrocodone rate, hydrocortisone, hydromorphone, hydroxyurea, hydroxyzine, ifosfamide, loprid, imidocarb dipropinate, impenem—cilastatin sodium, imipramine, inamrinone e, insulin, interferon alfa-2a (human recombinant), iodide (sodium/potassium), ipecac (syrup), e sodium, iron dextran, isoflurane, isoproterenol, isotretinoin, isoxsuprine, MER ll-l79PCT itraconazole, ivermectin, kaolin/pectin, ketamine, ketoconazole, ketoprofen, ketorolac tromethamine, lactulose, leuprolide, levamisole, levetiracetam, levothyroxine sodium, lidocaine, lincomycin, liothyronine sodium, lisinopril, lomustine (CCNU), lufenuron, lysine, magnesium, mannitol, marbofloxacin, mechlorethamine, ine, meclofenamic acid, medetomidine, medium chain cerides, medroxyprogesterone acetate, megestrol acetate, melarsomine, melatonin, meloxican, melphalan, meperidine, mercaptopurine, meropenem, metformin, methadone, methazolamide, methenamine mandelate/hippurate, methimazole, nine, methocarbamol, methohexital sodium, rexate, methoxyflurane, methylene blue, methylphenidate, prednisolone, metoclopramide, metoprolol, metronidaxole, tine, mibolerlone, midazolam milbemycin oxime, mineral oil, minocycline, misoprostol, mitotane, ntrone, morphine sulfate, moxidectin, naloxone, mandrolone decanoate, naproxen, narcotic (opiate) agonist analgesics, neomycin sulfate, gmine, niacinamide, nitazoxanide, nitenpyram, nitrofurantoin, nitroglycerin, nitroprusside sodium, nizatidine, novobiocin sodium, nystatin, octreotide acetate, olsalazine , omeprozole, ondansetron, opiate antidiarrheals, orbifloxacin, lin , oxazepam, ynin chloride, oxymorphone, oxytretracycline, oxytocin, pamidronate disodium, pancreplipase, pancuronium bromide, paromomycin sulfate, parozetine, pencillamine, general information penicillins, penicillin G, penicillin V potassium, pentazocine, pentobarbital sodium, pentosan polysulfate sodium, pentoxifylline, pergolide mesylate, phenobarbital, ybenzamine, pheylbutazone, ephrine, phenypropanolamine, phenytoin sodium, pheromones, parenteral phosphate, phytonadione/Vitamin K-l, pimobendan, piperazine, pirlimycin, piroxicam, polysulfated glycosaminoglycan, ponazuril, potassium chloride, pralidoxime chloride, prazosin, prednisolone/prednisone, primidone, namide, procarbazine, prochlorperazine, propantheline bromide, nibacterium acnes injection, propofol, propranolol, protamine sulfate, pseudoephedrine, psyllium hydrophilic mucilloid, stigmine bromide, pyrilamine maleate, thamine, rine, quinidine, ranitidine, rifampin, s-adenosyl-methionine (SAMe), /hyperosmotic laxative, selamectin, selegiline /l-deprenyl, sertraline, sevelamer, sevoflurane, silymarin/milk thistle, sodium bicarbonate, sodium polystyrene sulfonate, sodium stibogluconate, sodium sulfate, sodum thiosulfate, somatotropin, sotalol, spectinomycin, spironolactone, stanozolol, streptokinase, streptozocin, succimer, succinylcholine chloride, sucralfate, sufentanil citrate, sulfachlorpyridazine sodium, sulfadiazine/trimethroprim, 2012/054719 MER 11-179PCT sulfamethoxazole/trimethoprim, sulfadimentoxine, sulfadimethoxine/ormetoprim, sulfasalazine, taurine, tepoxaline, terbinafline, terbutaline sulfate, testosterone, tetracycline, thiacetarsamide sodium, thiamine, thioguanine, thiopental sodium, thiotepa, thyrotropin, tiamulin, ticarcilin disodium, tiletamine /zolazepam, tilmocsin, tiopronin, tobramycin sulfate, tocainide, tolazoline, amic acid, topiramate, tramadol, trimcinolone ide, trientine, tane, raxine tartrate w/prednisolone, tripelennamine, tylosin, urdosiol, valproic acid, vanadium, vancomycin, vasopressin, vecuronium bromide, verapamil, vinblastine sulfate, vincristine sulfate, vitamin E/selenium, warfarin sodium, xylazine, yohimbine, zafirlukast, zidovudine (AZT), zinc acetate/zinc sulfate, zonisamide and mixtures f.

In one embodiment of the invention, razole compounds such as phenylpyrazoles, known in the art may be combined with the isoxazoline compounds in the topical compositions of the invention. Examples of such arylpyrazole compounds include but are not limited to those described in US. Patent Nos. 384; 6,010,710; 519; 6,096,329; 6,174,540; 6,685,954 and 6,998,131 (all of which are incorporated herein by reference, each assigned to Merial, Ltd., Duluth, GA).

In another embodiment of the invention, one or more macrocyclic lactones or lactams, which act as an ide, mintic agent and/or insecticide, can be added to the itions of the invention.

The macrocyclic lactones include, but are not limited to, avermectins such as abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, ctin, selamectin and 94,554, and milbemycins such as milbemectin, milbemycin D, moxidectin and nemadectin. Also included are the 5-oxo and e derivatives of said avermectins and milbemycins. Examples of combinations of arylpyrazole compounds with yclic lactones e but are not limited to those described in US. Patent Nos. 6,426,333; 6,482,425; 6,962,713 and 6,998,131 (all incorporated herein by reference - each assigned to Merial, Ltd., Duluth, GA).

The macrocyclic lactone compounds are known in the art and can easily be obtained commercially or through synthesis techniques known in the art. Reference is made to the widely available technical and commercial literature. For avermectins, ivermectin and abamectin, reference may be made, for example, to the work “Ivermectin and Abamectin”, 1989, by M.H.

Fischer and H. Mrozik, William C. Campbell, hed by Springer Verlag., or Albers- MER 11-179PCT Schonberg et al. , “Avermectins Structure ination”, J. Am. Chem. Soc., 103, 4216- 4221. For doramectin, “Veterinary Parasitology”, vol. 49, No. 1, July 1993, 5-15 may be consulted. For milbemycins, reference may be made, inter alia, to Davies H.G. et al., 1986, “Avermectins and ycins”, Nat. Prod. Rep., 3, 87-121, Mrozik H. et al., 1983, Synthesis of Milbemycins from ctins, Tetrahedron Lett., 24, 5333-5336, US. Patent No. 4,134,973 and EP 0 677 054.

Macrocyclic lactones are either natural products or are semi-synthetic derivatives thereof.

The structure of the avermectins and milbemycins are closely related, e. g., by sharing a x 16-membered macrocyclic lactone ring. The natural product avermectins are disclosed in US.

Patent No. 4,310,519 and the 22,23-dihydro avermectin compounds are disclosed in US. Patent No. 4,199,569. Mention is also made of US. Patent Nos. 4,468,390, 5,824,653, EP 0 007 812 A1, U.K. Patent Specification 1 390 336, EP 0 002 916, and New Zealand Patent No. 237 086, inter alia. Naturally occurring milbemycins are described in US. Patent No. 3,950,360 as well as in the various references cited in “The Merck Index” 12th ed., S. ri, Ed., Merck & Co., Inc. Whitehouse Station, New Jersey (1996). Latidectin is described in the “International prietary Names for Pharmaceutical Substances , WHO Drug Information, vol. 17, no. 4, pp. 263- 286, (2003). Semisynthetic derivatives of these classes of compounds are well known in the art and are described, for example, in US. Patent Nos. 5,077,308, 4,859,657, 4,963,582, 317, 4,871,719, 4,874,749, 4,427,663, 4,310,519, 569, 5,055,596, 4,973,711, 4,978,677, 148 and EP 0 667 054.

In preferred embodiment of the invention, the invention comprises a topical composition comprising an isoxazoline compound in combination with a class of acaricides or insecticides known as insect growth regulators (IGRs). Compounds belonging to this group are well known to the practitioner and represent a wide range of different chemical classes. These compounds all act by interfering with the development or growth of the insect pests. Insect growth regulators are described, for example, in US. Patent Nos. 3,748,356, 3,818,047, 4,225,598, 837, 4,751,225, EP 0 179 022 or UK. 2 140 010 as well as US. Patent Nos. 6,096,329 and 6,685,954 (all orated herein by reference).

In one embodiment the IGR is a compound that mimics juvenile hormone. Examples of juvenile hormone mimics include azadirachtin, olan, fenoxycarb, hydroprene, kinoprene, MER ll-l79PCT methoprene, pyriproxyfen, tetrahydroazadirachtin and 4-chloro-2(2-chloromethyl-propyl) (6-iodopyridylmethoxy)pyridazine-3(2H)-one.

In a particularly preferred embodiment, the itions of the invention comprise an isoxazoline nd of formula (I) in combination with methoprene or pyriproxyfen and a ceutically acceptable carrier. It has been surprisingly found that compositions comprising an isoxazoline compound of formula (I) in combination with methoprene or pyriproxyphen exhibit superior long lasting cy that is not predictable based on the activity of each active alone.

In another embodiment, the IGR compound is a chitin synthesis inhibitor. Chitin synthesis inhibitors e chlorofluazuron, cyromazine, diflubenzuron, fluazuron, flucycloxuron, xuron, hexaflumoron, lufenuron, tebufenozide, teflubenzuron, triflumoron, novaluron, l-(2,6-difluorobenzoyl)—3-(2-fluoro(trifluoromethyl)phenylurea, l-(2,6-difluorobenzoyl )(2-fluoro(l,l,2,2-tetrafluoroethoxy)-phenylurea and l-(2,6-difluorobenzoyl)—3-(2- 4-trifluoromethyl)phenylurea.

In yet another embodiment of the invention, cide insecticides and acaricides can also be added to the composition of the invention. These include pyrethrins (which include cinerin I, cinerin II, jasmolin I, jasmolin II, pyrethrin I, pyrethrin II and mixtures thereof) and pyrethroids, and carbamates ing, but are not limited to, benomyl, carbanolate, carbaryl, carbofuran, iocarb, metolcarb, promacyl, propoxur, aldicarb, butocarboxim, oxamyl, thiocarboxime and thiofanox.

In some ments, the compositions of the invention may include one or more antinematodal agents including, but not limited to, active agents in the benzimidazoles, imidazothiazoles, tetrahydropyrimidines, and organophosphate class of compounds. In some embodiments, benzimidazoles including, but not limited to, thiabendazole, cambendazole, parbendazole, oxibendazole, mebendazole, flubendazole, fenbendazole, oxfendazole, azole, cyclobendazole, febantel, thiophanate and its o,o-dimethyl analogue may be included in the compositions.

In other embodiments, the compositions may include an othiazole compounds including, but not limited to, tetramisole, levamisole and butamisole. In still other embodiments, the compositions of the invention may include tetrahydropyrimidine active agents including, but not limited to, pyrantel, oxantel, and morantel. Suitable organophosphate active agents include, MER ll-l79PCT but are not limited to, coumaphos, trichlorfon, haloxon, naftalofos and dichlorvos, heptenophos, mevinphos, monocrotophos, TEPP, and tetrachlorvinphos.

In other embodiments, the compositions may include the antinematodal compounds phenothiazine and piperazine as the neutral compound or in various salt forms, diethylcarbamazine, phenols such as disophenol, arsenicals such as mide, ethanolamines such as bephenium, thenium closylate, and methyridine; cyanine dyes including pyrvinium chloride, pyrvinium pamoate and dithiazanine iodide; ocyanates including bitoscanate, suramin sodium, phthalofyne, and various natural products including, but not limited to, hygromycin B, a-santonin and kainic acid.

In other ments, the compositions of the invention may include antitrematodal agents. Suitable antitrematodal agents include, but are not limited to, the miracils such as miracil D and mirasan; praziquantel, clonazepam and its 3-methyl tive, oltipraz, lucanthone, hycanthone, oxamniquine, amoscanate, niridazole, nitroxynil, various bisphenol nds known in the art including hexachlorophene, bithionol, bithionol sulfoxide and menichlopholan; s salicylanilide compounds including tribromsalan, oxyclozanide, clioxanide, rafoxanide, brotianide, bromoxanide and closantel; triclabendazole, netide, clorsulon, hetolin and emetine.

Anticestodal compounds may also be advantageously used in the compositions of the invention including, but not limited to, arecoline in various salt forms, bunamidine, niclosamide, nitroscanate, paromomycin and paromomycin II.

In yet other embodiments, the compositions of the invention may include other active agents that are ive against arthropod parasites. Suitable active agents include, but are not limited to, bromocyclen, chlordane, DDT, endosulfan, lindane, methoxychlor, toxaphene, bromophos, bromophos-ethyl, carbophenothion, envinphos, chlorpyrifos, crotoxyphos, cythioate, diazinon, dichlorenthion,, oate, hion, ethion, famphur, othion, fenthion, ate, iodofenphos, ion, naled, phosalone, phosmet, phoxim, propetamphos, ronnel, stirofos, allethrin, cyhalothrin, cypermethrin, deltamethrin, fenvalerate, flucythrinate, permethrin, phenothrin, pyrethrins, resmethrin, benzyl benzoate, carbon disulfide, crotamiton, diflubenzuron, diphenylamine, disulfiram, isobomyl thiocyanato acetate, rene, monosulfiram, pirenonylbutoxide, rotenone, triphenyltin acetate, nyltin hydroxide, deet, dimethyl ate, and the compounds l,5a,6,9,9a,9b-hexahydro-4a(4H)- MER ll-l79PCT dibenzofurancarboxaldehyde (MGK-l l), 2-(2-ethylhexyl)-3a,4,7,7a-tetrahydro-4,7-methano-lH- ole-l,3(2H)dione 64), dipropyl-2,5-pyridinedicarboxylate (MGK-326) and 2- (octylthio)ethanol (MGK-874).

In a particularly preferred embodiment, the topical compositions of the invention will include hrin in ation with the isoxazoline active agent.

An antiparasitic agent that can be combined with the compound of the invention to form a composition can be a biologically active peptide or protein including, but not d to, depsipeptides, which act at the neuromuscular junction by stimulating presynaptic ors belonging to the secretin receptor family resulting in the paralysis and death of parasites. In one embodiment of the depsipeptide, the depsipeptide is emodepside (see Willson et al., Parasitology, Jan. 2003, l26(Pt l):79-86).

In another embodiment, the compositions of the invention may comprise an active agent from the neonicotinoid class of pesticides. The neonicotinoids bind and inhibit insect specific nicotinic acetylcholine receptors. In one embodiment, the neonicotinoid insecticidal agent that can be combined with an isoxazoline compound to form a topical composition of the invention is imidacloprid. Imidacloprid is a well-known neonicotinoid active agent and is the key active ingredient in the topical parasiticide products Advantage®, Advantage® II, K9 Advantix®, and K9 Advantix® II sold by Bayer Animal Health. Agents of this class are bed, for example, in US. Patent No. 060 or in EP 0 892 060.

In another embodiment, the topical compositions of the invention may comprise nitenpyram, r active agent of the neonicotinoid class of ides. Nitenpyram has the following chemical structure and is the active ingredient in the oral product CAPSTARTM Tablets sold by Novartis Animal Health. \ w‘“ W 1111/ Nfig Nitenpyram is active against adult fleas when given daily as an oral tablet. yram works by interfering with normal nerve transmission and leads to the death of the insect.

Nitenpyram has a very fast onset of action t fleas. For example, CAPSTARTM Tablets begin to act against fleas in as early as 30 minutes after administration and is indicated for use as often as once a day. However, nitenpyram is only known to be effective when administered orally as MER ll-l79PCT a systemic parasiticide, as with CAPSTARTM Tablets. Therefore, it is surprising and unexpected that the topical compositions of the invention sing a combination of nitenpyram with an oline active agent exhibit the very fast onset of action of nitenpyram because this active agent is not known to be active when administered topically. The topical compositions of the invention comprising a ation of a long-lasting isoxazoline active agent with a very fast acting active agent such as the otinoid active agent nitenpyram provide optimal speed of onset and long lasting actiVity against ectoparasites.

Nitenpyram has a very low log octanol-water partition ient of -0.64 and a relatively high solubility in water of 840 g/L at 20° C and pH of 7 (see Supplement to Compendium on Continuing ion for the cing veterinarian, vol. 23, no. 3(a), march 2001), indicating that it is not a likely candidate for topical delivery. Based on the very low log p of nitenpyram and the very high water solubility, one of skill in the art would have a very high level of skepticism that this active agent could be effectively delivered in a topical composition.

The effectiveness of topical compositions of the invention that comprise nitenpyram are all the more unexpected in View of the physicochemical properties of the compound.

In r preferred embodiment of the invention, topical compositions comprising at least one isoxazoline compound in combination with an IGR and a neonicotinoid active agent are provided. In still r preferred embodiment, the invention provides topical compositions comprising an isoxazoline compound of Formula (I) together with an IGR that mimics juvenile hormone and nitenpyram. In yet another preferred embodiment, the invention provides topical spot-on or pour-on compositions comprising 3-chloro(trifluoromethyl)phenyl]-4,5- dihydro-S-(trifluoromethyl)-3 -isoxazolyl]-N- [2-oxo[(2,2,2-trifluoroethyl)amino] ethyl] - l - alanecarboxamide (Compound A) in combination with (S)-methoprene or pyriproxyfen and nitenpyram.

In another ment, the topical compositions of the invention provide topical spot-on or pour-on compositions that comprise 4-[5-[3-chloro(trifluoromethyl)phenyl]-4,5-dihydro (trifluoromethyl)-3 -isoxazolyl] -N-[2-oxo[(2,2,2-trifluoroethyl)amino] ethyl] - l - naphthalanecarboxamide (Compound A) in combination with nitenpyram, (S)—methoprene or pyriproxyfen and an avermectin or milbemycin compound. In yet another embodiment of the invention, topical itions are ed that comprise 4-[5-[3-chloro (trifluoromethyl)phenyl]-4,5-dihydro(trifluoromethyl)isoxazolyl]—N—[2-oxo[(2,2,2- MER 11-179PCT trifluoroethyl)amino]ethyl]naphthalanecarboxamide (Compound A) in combination with yram and/or (S)-methoprene or pyriproxyfen and/or an avermectin or milbemycin compound and/or praziquantel. In this embodiment, the presence of an avermectin or ycin compound and/or praziquantel provides potent activity against endoparasites in addition to activity against ectoparasites.

In certain embodiments, an insecticidal agent that can be combined with the compositions of the invention is a semicarbazone, such as metaflumizone.

In another embodiment, the compositions of the invention may ageously include a combination of isoxazoline compounds known in the art. These active agents are described in , WO 2007/075459 and US 2009/0133319, WO 2007/070606 and US 2009/0143410, , , , and US 2007/0066617 and WC 2008/122375, all of which are incorporated herein by reference in their entirety.

In another embodiment of the invention, nodulisporic acid and its tives (a class of known acaricidal, anthelmintic, anti-parasitic and icidal agents) may be added to the compositions of the invention. These compounds are used to treat or prevent infections in humans and animals and are described, for example, in US. Patent No. 5,399,582, 5,962,499, 6,221,894 and 6,399,786, all of which are hereby orated by reference in their entirety. The compositions may include one or more of the known nodulisporic acid derivatives in the art, including all isomers, such as those described in the patents cited above.

In r embodiment, anthelmintic compounds of the amino acetonitrile class (AAD) of compounds such as monepantel (ZOLVIX), and the like, may be added to the compositions of the ion. These compounds are described, for example, in WO 24704 and US.

Patent No. 7,084,280 porated by reference); Sager et al., Veterinary tology, 2009, 159, 49-54; Kaminsky et al., Nature vol. 452, 13 March 2008, 176-181. The compositions of the invention may also include aryloazolyl cyanoethylamino compounds such as those described in US Patent No. 8,088,801 to Soll et al., which is incorporated herein in its entirety, and thioamide derivatives of these compounds, as described in US. Patent No. 7,964,621, which is incorporated herein by reference.

The compositions of the invention may also be combined with paraherquamide nds and derivatives of these compounds, including derquantel (see Ostlind et al., MER 11-179PCT Research in Veterinary Science, 1990, 48, 260-61; and Ostlind et al., Medical and nary Entomology, 1997, 11, 407-408). The paraherquamide family of compounds is a known class of compounds that include a spirodioxepino indole core with activity against n parasites (see Tet. Lett. 1981, 22, 135; J. Antibiotics 1990, 43, 1380, and J. Antibiotics 1991, 44, 492). In addition, the structurally related rtine family of compounds, such as marcfortines A-C, are also known and may be combined with the ations of the invention (see J. Chem. Soc. — Chem. Comm. 1980, 601 and Tet. Lett. 1981, 22, 1977). Further references to the paraherquamide derivatives can be found, for example, in WO 91/09961, WO 92/22555, WO 97/03988, WO 01/076370, WO 09/004432, US. Patent 5,703,078 and US. Patent 5,750,695, all of which are hereby incorporated by nce in their entirety.

In general, the onal active agent is included in the composition in an amount of between about 0.1 ug and about 1000 mg. More typically, the additional active agent may be included in an amount of about 10 ug to about 500 mg, about 1 mg to about 300 mg, about 10 mg to about 200 mg or about 10 mg to about 100 mg.

In other ments of the invention, the additional active agent may be included in the ition to deliver a dose of about 5 ug/kg to about 50 mg/kg per weight of the animal. In other embodiments, the additional active agent may be present in an amount ient to deliver a dose of about 0.01 mg/kg to about 30 mg/kg, about 0.1 mg/kg to about 20 mg/kg, or about 0.1 mg/kg to about 10 mg/kg of weight of animal. In other embodiments, the additional active agent may be present in a dose of about 5 ug/kg to about 200 ug/kg or about 0.1 mg/kg to about 1 mg/kg of weight of animal. In still another embodiment of the invention, the additional active agent is included in a dose between about 0.5 mg/kg to about 50 mg/kg.

The topical itions of the invention, which include at least an isoxazoline active agent and a pharmaceutically acceptable carrier that is suitable for topical application to an animal, have been singly discovered to be stable and effective against a broad um of ectoparasites for an extended period of time.

In a preferred embodiment of the inventive compositions, the topical composition will be in the form of a liquid solution or sion that comprises a pharmaceutically acceptable carrier or diluent that is suitable for application to the skin of an animal. Topical, dermal and subdermal formulations can include emulsions, creams, ointments, gels, pastes, powders, shampoos, pour-on formulations, ready-to-use formulations, spot-on solutions and suspensions.

MER ll-l79PCT In a preferred embodiment of the ion, topical compositions suitable for topical stration to a localized area of an animal are provided, including itions in the form of spot-on or pour-on compositions. In another embodiment, the topical compositions will be in the form of a spray formulation, an aerosol or a foam formulation suitable for administration to an animal. In some embodiments, the liquid solution or suspension ations comprising isoxazoline active agents will be in a form that can be sprayed on via a metered dose pump or a metered dose aerosol.

Isoxazoline active agents, such as those of Formula (I), are systemically active such that the ectoparasite is affected when taking a blood meal from the host. Accordingly, a m concentration of the compounds in the ic circulation of the animal is required. However, in some situations the isoxazoline active agent may also be active by contacting the parasite on the surface of the animal. Thus, in some embodiments, topical application of the inventive itions can allow for the active agents to be delivered and distributed throughout the hair coat topically and/or may also provide distribution of the active agent via the sebaceous glands of the animals. When the compound is distributed hout sebaceous glands, the sebaceous glands can act as a reservoir, whereby there can be a long-lasting effect, e.g. at least one month or longer. For example, Cochet and co-workers reported the distribution of f1pronil, a l- arylpyrazole compound, to the stratum comeum, the viable epidermis and the sebaceous glands and epithelial layers of beagle dogs after spot-on administration (see Cochet et al., Eur. J. Drug Metab. Pharmacokinet.., 1997, 22(3), 211-216). Using 14C radiolabeled drug, the publication demonstrated that f1pronil is displaced from the point of application and buted to the whole skin, where it was tently detected for up to 56 days after treatment.

Topical application of the ive compositions enables effective delivery of the active agent transdermally through the skin into the systemic circulation at a concentration sufficient to provide excellent efficacy against ectoparasites. In another preferred embodiment, the compositions of the invention achieve distribution of the active agent both topically over the hair coat of the animal and also transdermally into the blood stream. In this embodiment, the topical itions provide a high level of efficacy at unexpectedly low plasma trations of the isoxazoline active agent.

The outer layer of the epidermis, the stratum comeum, forms the major barrier to both the egress of water and the ingress of xenobiotics into the atory system. It is a unique MER ll-l79PCT membrane comprised of dead thin flat cells, comeocytes, which are filled with dense keratin, between which is a lipid-rich layer comprised of us lipid bilayers. The general consensus is that most xenobiotics pass through the lipid-rich layer between the flat cells. Delivering an active through the skin presents a significant challenge, given the role of the skin as a barrier for g foreign nces out. In order for an active ingredient to pass through the stratum comeum, it must pass sequentially across bilayers and ore cross many hydrophilic- lipophilic interfaces. Because of the efficient barrier of the skin, transdermal delivery is only typically appropriate for potent compounds that require only a small .

Only materials which have good solubility properties in both oils and water will be able to effectively pass across the skin with relative ease. One of the major problems in ng the skin or using the skin to deliver a nce into the systemic circulation arises from the requirement that the active has to possess the t physicochemical properties to allow it to reach the site of action or circulation. If it is extremely hydrophilic it will reside on the skin surface. If it is extremely lipophilic it will pass into the lipid-rich layer between the cells and will have lty ating deeper. Only compounds that are small, have balanced solubility in oils and water and a log (octanol—water partition coefficient) of ~2 (log P) will pass through the stratum comeum and into the systemic circulation to any significant degree (see Kenneth B.

Sloan (ed.) (1992) Prodrugs: Topical and Ocular Drug Delivery, p.6, Marcel Dekker, New York). Examples include nicotine and nitroglycerin (GTN). However even these are not absorbed to a large degree. Thus, many compounds are not suitable for transdermal delivery because of their inherent physicochemical properties.

It will be tood that the ability of an active agent to be distributed either topically or transdermally is dependent both on the physicochemical characteristics of the compound and also on the non-active ents of the formulation, which may induce penetration of the active agent into the skin. While there is no general method to deliver any active agent either topically over the hair coat of an animal or transdermally to an animal, some techniques for enhancing the penetration of active agents into the skin of animals are known. Substances termed “permeation enhancers,” are typically used in itions ed to deliver drugs transdermally to increase the amount of the active that is delivered into the systemic circulation. Permeation enhancers constitute various classes of compounds including n solvents such as dimethylsulfoxide (DMSO), pyrrolidones, ethanol, propylene glycol, ethyl acetate, MER ll-l79PCT dimethylacetamide, and others that are capable of disrupting the barrier function of the stratum comeum. Other substances have also been shown to increase the flux of certain active agents through the skin. These include lipophilic compounds such as apram (Azone); fatty acids or alcohols such as oleic acid, oleyl alcohol, linoleic acid and the like; certain fatty acid esters such as isopropyl myristate, methyl noanoate, methyl e and others. Mixtures of certain permeation enhancers with propylene glycol are also known to improve the delivery of certain active ingredients. For example, see ceutical Skin Penetration Enhancement edited by Kenneth A. Walters and Jonathan Hadgraft, Marcel Dekker, Inc. New York, 1993; ISBN 0 9017-0.

In some embodiments of the invention, the compositions are formulated to control the rate of tion of the isoxazoline compound in order to maintain efficacious levels of the active in the plasma for a prolonged period of time and significantly extend the duration of efficacy. Thus, in one embodiment, the topical compositions of the invention are formulated with a carrier system that induces the containment of the isoxazoline active agent(s) within the skin to achieve a reservoir effect and controls the permeation rate of the compound into the systemic circulation over a longer period of time. In this manner, the invention provides topical compositions that exhibit surprising long lasting efficacy against ectoparasites. It must be noted that this ch is only applicable to potent active agents that may achieve the d parasiticidal cy with low plasma concentrations, since less potent compounds would not be able to establish an cious concentration.

It has been found that the topical itions of the present invention comprising an isoxazoline active agent in a carrier comprising a ilic solvent or lipophilic solvent system result in superb cy against ectoparasites for an extended duration of time. Although not wishing to be bound by theory, it is believed that non-active excipients in certain l formulations of the invention promote the containment of the isoxazoline active agent within the skin for longer periods of time while allowing the active agent to constantly diffilse into the circulatory system at a rate that provides the required concentration of the active in the blood stream to be efficacious against ectoparasites for a longer period of time. This is contrary to the approaches used with typical l ations that are designed to enhance the passage of active agents through the skin of an animal into the systemic circulation quickly to obtain the desired biological effect. Thus, in one embodiment the present ion utilizes non-active MER ll-l79PCT excipients that discourage the fast permeation of oline active agents into the systemic circulation.

In one embodiment, the ion provides topical compositions comprising an isoxazoline active agent in a pharmaceutically acceptable carrier wherein the carrier does not include a compound that enhances the permeation of the isoxazoline active agent. In another embodiment, the ion provides topical compositions comprising an isoxazoline active agent and a pharmaceutically acceptable carrier wherein the carrier comprises a solvent or solvent system that promotes the containment of the isoxazoline active agent in the skin of the animal for a longer period of time.

In one embodiment of the invention comprising a r that extends the duration of efficacy of the topical itions, the carrier may comprise a solvent selected from carboxylic acid esters, diesters of dicarboxylic acids, fatty acid esters or diesters of fatty diacids, or a combination thereof, including, but not limited to, isopropyl palmitate, isostearyl lactate, ropyl adipate, dibutyl adipate, diethyl sebacate, dibutyl sebacate, octyl palmitate, polyethyleneglycol (PEG) stearate and yl octanoate; oils including, but not limited to, mineral oil, diglycerides, triglycerides, jojoba oil, lecithin and castor oil, or a combination thereof; long chain aliphatic alcohols such as isostearyl alcohol and the like; fatty alcohols and their , including for e, cetyl alcohol, cetearyl alcohol and the like, or a combination thereof; polyethylene glycols of different molecular weight ranges including, but not limited to, PEG 300, PEG 400, PEG 600 and PEG 1000, or a combination thereof; and glycol ethers ing, but not limited to, diethyleneglycol monoethyl ether (Transcutol®), butyl diglycol, ene glycol monomethyl ether, propylene glycol monoethyl ether, dipropylene glycol nbutyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether and ylene glycol monomethyl ether, or a combination f; or a combination of two or more of these solvents.

Excipients that may also promote the containment of the active agent in the skin for longer periods of time and may be included in the compositions of the invention include, but are not limited to, mixed esters of sucrose and carboxylic acids including sucrose acetate isobutyrate (SAIB) and the like; low temperature melting waxes, hydrogenated ble oils, caprylic/capric ides; glycerol esters, including for example, triacetin, glycerol monooleate, glycerol monolinoleate, glycerol stearate, glyceryl distearate and the like; cerides, including 2012/054719 MER ll-l79PCT for example, caprylic, / myristic/ stearic triglyceride; thermoreversible polymers, such as Pluronic and poloxamers, including for example, Lutrol F127 by itself or in mixture with other poloxamers; or a combination f.

In r embodiment of the ion the pharmaceutically acceptable carrier for the topical compositions comprise a mixture of a diester of a dicarboxylic acid alone or in combination with one or more of additional solvents listed above, and/or an “oily” lipophilic substance, including a liquid or low melting lipophilic active agent such as (S)-methoprene, pyriproxyfen and/or permethrin; and/or a mixed ester of sucrose and carboxylic acids including a mixed ester of sucrose and acetic and isobutyric acids such as e e yrate (SAIB), and/or low melting waxes and/or hard fats.

Although not wishing to be bound by theory, the inclusion of n lipophilic solvents in the topical compositions of the invention promote the nce time of the isoxazoline active agent within the skin while allowing an effective concentration of the active agent to pass slowly into the circulatory system to achieve the desired y for longer periods of time.

In a preferred embodiment, the diester of a dicarboxylic acid is diethyl sebacate or diisopropyl adipate. In another embodiment, the blend of solvents comprising a dicarboxylic acid ester comprises a glycol or polyglycol, or a glycol or polyglycol ether or ester including, but not limited to, ethylene glycol (EG), propylene glycol (PG), liquid polyoxyethylene glycols (PEGs) of various grades including PEG 400, EG or PG monocaprylate, EG or PG caprylate, EG or PG monolaurate, EG or PG dicaprylate/dicaprate, diethyleneglycol monoethyl ether (DGME, Transcutol®), butyl diglycol, ylene glycol n-butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like, or a combination thereof; an ether including, but not limited to, dimethyl isosorbide; an ester or di- ester including, but not limited to, triacetin, lauryl lactate; and other solvents including glycerol formal, or mixtures thereof.

In preferred embodiments, the r for the topical compositions comprises a dialkyl ester of a dicarboxylic acid such as diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, dibutyl adipate, or a combination thereof, alone or in ation with solvents selected from: a) a propylene glycol (PG) ester including PG monocaprylate, PG caprylate, PG monolaurate, PG ylate / dicaprate, or a ation thereof; MER 11-179PCT b) an ether solvent ing dimethyl isosorbide, diethylene glycol hyl ether (also known as DGME or Transcutol®), or a combination thereof; c) a carboxylic acid ester including, but not d to, triacetin, lauryl lactate, isopropyl palmitate, diisopropyl sebacate, or a combination thereof; and d) other “oily” or lipophilic organic solvents ing ol formal and the like.

In some embodiments, the amount the additional solvents combined with the carboxylic acid ester or diester of a dicarboxylic acid are present in an amount of at least about 1% (V/V), at least about 5% (v/v), at least about 9.0% (v/v), at least about 13% (v/v), at least about 17% (v/v) or at least about 20% (V/V). Preferably the additional solvents will be in an amount of at least about 9% (v/v).

In other embodiments, the additional solvents will be present in an amount of about 5- 70% (v/v), about 10-60% (v/v), about 10-50% (v/v), about 15-60% (v/v) or about 15-50% (v/v).

In preferred ments, the additional solvents will be present in an amount of about 20-70% (v/v), about 20-60% (v/v), about 20-50% (v/v) or about 25-50% (v/v).

The pharmaceutically acceptable carrier may include le carriers or diluents ly used in the formulation art including aqueous or organic solvents or mixtures of solvents. These organic solvents may be found, for example, in Remington Pharmaceutical Sciences, 21St Edition (2005). Other solvents and/or ves that may be used in the topical compositions include, but are not limited to, PEG ethers and PEG esters including, but not limited to, PEG esters of carboxylic acids and dicarboxylic acids and PEG esters of fatty acids, glycerol esters including triacetin, caprylic/capric triglycerides (Miglyol 812®) and the like; glycerol ethers including glycerol formal; propylene glycol dicaprylate/dicaprate (Miglyol 840®), lauryl lactate, triacetin, diisopropyl adipate (DIPA, also known as CERAPHYL 230), diisobutyl adipate, dimethyl isosorbide (DMI), tributyl citrate, oleic acid; carboxylic acid esters including esters of diacids, ketones including acetone, methylisobutyl ketone (MIK), methyl ethyl ketone, and the like; itrile, C1-C12 alcohols including benzyl alcohol, methanol, ethyl l, isopropanol, and butanol; ic ethers such as anisole; amides including dimethylacetamide, monomethylacetamide and dimethylformamide; dimethyl sulfoxide (DMSO), ethylene glycol, propylene glycol, a glycol carbonate including, but not limited to, propylene carbonate and, butylene ate; 2-pyrrolidone, N—methylpyrrolidone, C1-C12 alkyl MER ll-l79PCT esters of carboxylic acids ing butyl or octyl acetate and benzyl e; C1-C12 alkyl esters of dicarboxylic acids; aryl esters including benzyl benzoate, ethyl benzoate and the like; and diethyl ate, or a mixture of at least two of these solvents.

However, in one embodiment, the invention provides topical compositions comprising at least one isoxazoline active agent, optionally in ation with one or more additional active agents, in a pharmaceutically acceptable carrier, wherein the carrier does not comprise glycofurol. In another embodiment, the ceutically able carrier of the topical compositions does not comprise a binary mixture of propylene glycol and glycerol formal.

As vehicle or diluent, mention may also be made of plant oils such as, but not limited to soybean oil, groundnut oil, castor oil, corn oil, cotton oil, olive oil, grape seed oil, sunflower oil, etc.; mineral oils such as, but not limited to, petrolatum, paraffin, silicone, etc.; aliphatic or cyclic hydrocarbons including limonene or alternatively, for example, medium-chain (such as C8 to C12) triglycerides, or mixtures thereof.

In one embodiment, solvents and/or additives that control the permeation rate of the active may be added to a composition comprising one of the formulation carriers described herein, including rs comprising a l ester of a dicarboxylic acid such as diethyl sebacate or the like. In another embodiment, solvents and/or additives that control the permeation rate of the active may be added to carriers comprising other solvents described herein or may be used alone in the composition.

It will be appreciated by those skilled in the art that the skin of different animals will be different in nature and may be more or less permeable to the isoxazoline active agent. For example, the retainment of the isoxazoline active agent on the skin of a cat may be more difficult than dogs. Accordingly, in some situations with certain animals the topical compositions of the invention will utilize solvents that enhance the permeation of the isoxazoline active agent h the skin of the animal rather than solvents and excipients that retain the active agent on the skin of the animal for longer s of time. Thus, in another embodiment of the invention, l compositions are provided that include ts that enhance the permeation of isoxazoline active agents through the skin of the animal. These ts provide a greater proportion of the active agent through the skin and thereby improve the efficacy and duration of time. In this embodiment, the permeation enhancing solvent permits a greater proportion of the isoxazoline active agent through the skin into the ic circulation. It will be appreciated by MER ll-l79PCT those of skill in the art that this effect allows a greater level of efficacy at lower doses of the active. Selected solvents that enhance the permeation of the isoxazoline active agent include, but are not limited to, dimethyl isosorbide; and glycol ethers ing, but not limited to, diethyleneglycol monoethyl ether (DGME, Transcutol®), butyl diglycol, dipropylene glycol n- butyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like. Other solvents that enhance the permeation of the isoxazoline active agent described below may also be used in the compositions.

In one embodiment of the invention, the pharmaceutically acceptable carrier of the formulation may comprise C8-C20 long-chain aliphatic alcohols or esters thereof. In another embodiment, the carrier comprises C1-C12 ls or esters thereof, C1-C4 alcohols or esters thereof or C3-C8 alcohols or esters thereof. In some embodiments, the esters formed with the l include esters of C1-C12 carboxylic acids or diacids, or esters of C6-C16 carboxylic acids or diacids. Esters include, but are not d to, es such as ethyl acetate and the like; and esters of C1-C9 ls and a dicarboxylic acid or a hydroxy-substituted carboxylic acids.

In r ment, the pharmaceutically acceptable carrier comprises C4-C22 fatty acids or esters thereof, including esters with C6-C20 long chain alcohols, C1-C12 alcohols, C1-C4 ls or C3-C8 alcohols; Clo-C18 saturated fatty acids or esters thereof, including esters with C6-C20 long chain alcohols, C1-C12 alcohols, C1-C4 alcohols or C3-C8 alcohols; Clo-C18 rated fatty acids or esters thereof, ing esters with C6-C20 long chain alcohols, C1-C12 alcohols, C1-C4 alcohols or C3-C8 ls; monoesters or diesters of C6-C16 aliphatic carboxylic acids and carboxylic diacids, including esters with C6-C20 long chain alcohols, C1-C12 alcohols, C1-C4 alcohols or C3-C8 alcohols, or mixtures f In other embodiments, the carrier may include C1-C10, C1-C8 or C1-C6 alcohols or esters thereof.

In another embodiment, the compositions of the invention comprise aromatic alcohols or esters thereof. In one preferred embodiment, the topical compositions of the ion may include benzyl alcohol as a solvent.

In another embodiment, preferred solvents include C1-C12 alkyl esters of ylic acids such as butyl acetate, octyl acetate, lauryl lactate or isopropyl palmitate, and C1-C9 alkyl esters of dicarboxylic acids, including diisopropyl adipate, diethyl sebacate and diisopropyl sebacate. In other embodiments, the carrier may include C1-C10, C1-C8 or C1-C6 alkyl esters of carboxylic MER ll-l79PCT acids or C1-C10, C1-C8 or C1-C6 alkyl diesters or dicarboxylic acids. In one embodiment, the carboxylic acid or dicarboxylic acid is a C4-C2 fatty acid or dicarboxylic acid. In another embodiment, the carboxylic acid or dicarboxylic acid is a C1-C12 carboxylic acid or dicarboxylic acid. In other embodiments, the carboxylic acid or dicarboxylic acid is a , C1-C8 or C1-C6 carboxylic acid or dicarboxylic acid.

In some preferred embodiments, the carrier or diluent include a derivative of glycerol including, but not limited to, glycerol ters (e.g. monoglycerides), glycerol diesters (e.g. diglycerides), glycerol triesters (e.g. triglycerides such as triacetin), or glycerol formal, or mixtures thereof. Glycerol formal is a mixture of 5-hydroxy-l,3-dioxane and oxymethyl- 1,3- dioxolane (approximately 60:40), which are cyclic ether compounds d from glycerol and having 2 oxygen atoms in the ring structure and substituted by alcohol group. Glycerol Formal is a low odor and low toxic solvent for a wide variety of applications in pharmaceutical and ics industry including arasite veterinary formulations.

In r embodiment of the invention, the organic solvents may comprise diisopropyl adipate, ylene glycol monomethyl ether, propylene glycol monomethyl ether, 2- pyrrolidone, N—methylpyrrolidone, diethylene glycol monoethyl ether, triacetin, butyl acetate, benzyl alcohol, octyl acetate, propylene carbonate, oleic acid, or a mixture of at least two of these solvents.

In some embodiments of the invention, the carrier comprises dimethyl isosorbide.

Dimethyl isosorbide (DMI) is a high purity solvent and r which offers a safe, effective delivery enhancement mechanism for active ingredients in al care products and pharmaceutical formulations. In addition dimethyl isosorbide is sometimes used as an epidermal penetration enhancer to provide enhanced penetration of active agents to the epidermis. It may also provide delivery of active agents into the skin while avoiding crystallization of the active agent, which will severely limit the effectiveness of the formulation. Dimethyl Isosorbide is soluble in a variety of ingredients including water, cottonseed oil, panol, isopropyl myristate, propylene glycol, polysorbate 20, and polysorbate 80.

In other embodiments, the carrier or diluent may comprise a glycol tive including, but not limited to, propylene , ethylene glycol; glycol ethers and polyglycol ethers ing, but not limited to, butyl ol, propylene glycol monomethyl ether, propylene glycol hyl ether, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, 2012/054719 MER ll-l79PCT ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, and diethylene glycol monoethyl ether (DGME or Transcutol®).

In a preferred embodiment, the topical itions of the invention comprising isoxazoline active agent(s) are dissolved in a pharmaceutically acceptable carrier sing one or more solvents. In some embodiments of the invention ts include, but are not limited to, dimethyl isosorbide (DMI), glycerol formal (methylidinoglycerol or glycerin formal), triacetin, liquid polyethyleneglycols including PEG 400, diisopropyl adipate (DIPA), isopropyl palmitate, silicone fluid including SILICONE FLUID 200 and Silicone Fluid lcst and /or Silicone Fluid 2cst and the like; propylene glycol (or other aliphatic dihydric alcohols), benzyl alcohol, ene glycol esters including propylene glycol dicaprylate / dicaprate, ene carbonate, propylene glycol monocaprylate, propylene glycol dicaprylate, propylene glycol monolaurate and propylene glycol dilaurate; alkyl esters of dicarboxylic acids including l sebacate (DES), diisopropyl sebacate; and esters or diesters of fatty acid, or combinations thereof In an embodiment of the invention, the itions of the invention may include surfactants. The surfactants may be anionic, cationic, non-ionic or amphoteric surfactants.

Anionic surfactants include, but are not limited to, alkaline tes; calcium stearate; triethanolamine stearate; sodium abietate; alkyl sulfates; sodium dodecylbenzenesulphonate, sodium dioctylsulphosuccinate; fatty acids, and the like. Examples of cationic surfactant include, but are not limited to, water-soluble quaternary ammonium salts of formula; cetyltrimethylammonium bromide and octadecylamine hydrochloride. Non-ionic surfactants that may be used in the compositions include, but are not limited to, yethylenated (PEGylated) esters including, but not limited to, sorbitan esters and fatty acid esters; polyethylene glycol stearate, polyoxyethylenated derivatives of castor oil, ycerol esters, polyoxyethylenated fatty alcohols, yethylenated fatty acids, and copolymers of ethylene oxide and propylene oxide including, but not limited to, block co-polymers of ethylene oxide and ene oxide such as poloxamers and the like (e.g. Lutrol® F grades and L grades from BASF including Lutrol® F68, F87, F 108 and F 127 and others), and the like;. Further example of tants include, but are not limited to, CAPRYOLTM 90 (propylene glycol prylate), CAPRYOLTM PGMC (propylene glycol monocaprylate) which are oily liquids having an HLB (hydrophilic-lipophilic balance) of 6 and 5, respectively. Topically they can be used as a co- surfactant in microemulsions and as a solubilizer/penetration enhancer.

WO 39948 MER ll-l79PCT As used herein, HLB values have the ing general meanings: compounds with a HLB value of < 10 tend to be lipid soluble (water insoluble) and solvents with a HLB > 10 tend to be water soluble. Surfactants having HLB between 4 and 8 are typically useful as anti-foaming agents. Surfactants having HLB from 7 to 11 may be useful as W/O (water in oil) emulsifiers.

HLB of 12 to 16 typically tes a surfactant may be useful in oil in water emulsions, and HLB of 11 to 14 is indicative of a wetting agent. HLB of 12 to 15 is typical of detergents, and HLB of 16 to 20 indicates a solubilizer or hydrotrope. There is significant an overlap of /uses, and a skilled person well understands that the HLB value alone cannot be used to predict whether a particular surfactant will serve a specific purpose (e.g. anti-foaming agent, emulsifier, g agent, solubilizer, hydrotrope). Therefore, in general, determination of a suitable system of solvent, active agent, surfactant(s) and other excipients necessarily involves non-routine experimentation and inventive effort.

The compositions may also include tants such as oleoyl macrogolglycerides (polyoxylglycerides, for example, LABRAFIL® M1944CS and LABRAFIL® M2125CS both having an HLB of 4). These compounds may also be used, for example, as oily phase for emulsions, microemulsions, and as penetration enhancers.

In another embodiment, the polyoxylglycerides may include polyethyleneglycol caprylic/caprylic glycerides such as OL® (HLB of 14. Topically it is used as a surfactant in microemulsions, and can also act as a lity/penetration enhancer in topical formulations.

In another embodiment the tant is LAUROGLYCOLTM90 (propylene glycol monolaurate) having an HLB of 5. It is a co-surfactant for microemulsions in topical formulations and can also act as a solubilizer/penetration enhancer in topical formulations. In some embodiments, the surfactant is PLUROL® E CC497 (polyglyceryl oleate), having an HLB of 6.

Certain ts suitable for topical formulations may be characterized as having good spreading properties while other solvents for topical formulations may be characterized by an y to enhance permeation of active agents through the skin barrier into the systemic circulation (see for example, Pharmaceutical Skin ation Enhancement, edited by Jonathan Hadgraft and Kenneth A. Walters, Marcel Dekker, Inc. New York 1993). In some instances, solvents suitable for topical formulations may e both good spreading and good permeation MER ll-l79PCT characteristics. DIPA, diisopropyl sebacate, DES and Miglyol 840 have both good spreading and permeation characteristics. utol, DMI, lauryl lactate, propylene glycol caprylate, propylene glycol monocaprylate and propylene glycol monolaurate have good tion enhancing properties but are not considered to have particularly good spreading properties. In certain embodiments of the invention, the compositions will se mixtures of solvents that will enhance the spreading ability and/or the permeation enhancing ability of the composition.

In some embodiments of the invention, formulations are provided wherein the r comprises ts that exhibit both good spreading and permeation characteristics including, but not limited to, DIPA, diisopropyl sebacate, DES and Miglyol® 840. In other embodiments, the ion provides ations wherein the carrier comprises solvents that exhibit good spreading characteristics. In still another embodiment of the invention, formulations are provided wherein the carrier vehicle comprises solvents that enhance the tion of the active agent through the skin into the systemic circulation.

In one embodiment, the composition exhibits long lasting efficacy and provides protection against parasites in domestic animals for at least one month. In one embodiment, the composition comprises a carrier that includes a solvent system comprised of a carboxylic acid alkyl ester or diester of a dicarboxylic acid. In another embodiment, the composition comprises a blend of solvents comprising a carboxylic acid alkyl ester or a diester of a dicarboxylic acid.

In r embodiment, the compositions of the invention exhibit very long lasting efficacy of at least 90% t fleas and/or ticks that for a period of at least 1 month, at least 2 months, at least 3 , at least 4 months, at least 5 months, or at least 6 months against fleas and/or ticks. In one embodiment, the long-lasting composition comprises a carrier that includes a carboxylic acid alkyl ester or a diester of a dicarboxylic acid, including diethyl te and diisopropyl adipate. In another embodiment, the long-lasting composition comprises a carboxylic acid alkyl ester or a diester of a dicarboxylic acid combined with an co-solvent including, but not limited to, a propylene glycol (PG) ester including PG monocaprylate, PG caprylate, PG monolaurate and PG dicaprylate/dicaprate; diethyleneglycol monoethyl ether (DGME, Transcutol®), l oil, triglycerides, diglycerides, isostearyl alcohol, isostearyl lactate, dibutyl adipate, l sebacate; polyethylene glycols (PEGs) including PEG 400, PEG stearate; lecithin, castor oil and castor oil derivatives, film formers, myristyl myristate, iconol argenine, sucrose acetyl yrate, and the like, or a combination thereof.

MER ll-l79PCT In still another embodiment, the long-lasting compositions that provide an y of at least 90% against fleas and/or ticks for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months, comprise a carrier vehicle that includes yl isosorbide. As mentioned above, DMI is a known permeation er, and use of this solvent in some topical formulations of the ion results in increased delivery of the active agent into the systemic circulation. In particular, it was found that the use of DMI in l formulations for cats resulted in surprising efficacy for up to at least 3 months, at least 4 months, at least 5 months or even at least 6 months, against fleas.

In yet another embodiment, the long-lasting compositions that provide an efficacy of at least 90% against fleas and/or ticks comprises a glycol ether including, but not d to, diethyleneglycol monoethyl ether (DGME, Transcutol®), butyl diglycol, dipropylene glycol nbutyl ether, ethyleneglycol monoethyl ether, ethyleneglycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, and the like.

As discussed above, isoxazoline active agents such as those of Formula (I), and in particular 4-[5-[3-chloro(trifluoromethyl)phenyl]-4,5-dihydro(trifluoromethyl) isoxazolyl]—N—[2-oxo[(2,2,2-trifluoroethyl)amino] ethyl] - l -naphthalanecarboxamide (Compound A), are systemically active such that the rasite is affected when taking a blood meal from the host. Accordingly, a minimum tration of the compounds in the systemic circulation of the animal is required to effectively control rasites such as ticks and fleas. It was surprisingly found that the topical formulations of the invention comprising an isoxazoline active agent provide ent efficacy against fleas and ticks at unexpectedly very low plasma concentrations. In some embodiments, the topical compositions of the invention comprising selected solvents and excipients, including dialkyl esters of dicarboxylic acids such as diethyl sebacate and the like, result in nt low levels of the active agent over a ged period of time. In some embodiments, the concentration of the active agent in the plasma that is sufficient to obtain at least 90% efficacy against fleas and/or ticks is less than or equal to about 200 ng/mL or less than or equal to about 150 ng/mL. In other preferred embodiments, the concentration of the isoxazoline active agent in the plasma required to attain 90% efficacy against fleas and/or ticks is less than or equal to abouthO ng/mL, less than or equal to about 75 ng/mL or even less than or equal to about 50 ng/mL. In other embodiments of the invention, the concentration of the MER ll-l79PCT isoxazoline active agent in the plasma required to attain 90% efficacy against fleas and ticks is about 75-100 ng/mL, about 50-75 ng/mL or about 30-50 ng/mL.

Furthermore, it was also surprisingly found that the concentration of the isoxazoline active agent (Compound A) in the plasma required to attain an efficacy of at least 90% against certain tick species compared to an untreated control or a l group d with a placebo was significantly less than the plasma concentration required to attain 90% efficacy from r mode of administration that achieves high systemic exposure, such as oral or injectable administration. It was found that the concentration of the isoxazoline active agent required to achieve 90% efficacy against the tick species A. anum, D. variabilis and R. sanguineus in dogs was about 42%, 36% and 32% lower than the concentration required from oral administration (see Example 13). This effect is surprising and unexpected for an active agent that is active against ectoparasites through ingestion of a blood meal, as with the isoxazoline class of nds. Although not wanting to be bound by theory, the lower plasma concentration required to achieve 90% efficacy from the topical compositions of the invention may indicate that the compositions provide protection against ectoparasites by acting both topically on the surface of the animal and systemically. The improved efficacy of the topical compositions of the invention t these tick species at significantly lower plasma concentrations may allow for a longer duration of efficacy based on the ability of the non-active excipients in the ive compositions to provide a slow delivery of ive amounts of isoxazoline active agents into the blood stream from the site of application.

As mentioned above, it was surprisingly ered that the addition of certain other active agents with the isoxazoline active agent in the l compositions of the invention significantly enhanced the long lasting efficacy of the compositions. For example, inclusion of an IGR active agent such as the juvenile hormone mimic rene in the l compositions resulted in significantly longer lasting efficacy against ectoparasites. Thus, in one preferred embodiment the ion provides very long lasting topical compositions comprising at least one isoxazoline active agent in combination with an insect growth regulator (IGR) active agent.

Preferably, the IGR will be a juvenile hormone mimic including azadirachtin, olan, fenoxycarb, hydroprene, kinoprene, pyriproxyfen, tetrahydroazadirachtin or 4-chloro(2- chloromethylpropyl)(6-iodopyridylmethoxy)pyridizin-3(2H)-one, as sed herein.

More preferably, the IGR will be methoprene or pyriproxyfen. As described in the non-limiting MER 11-179PCT es, the ion of the IGR (S)-methoprene with the isoxazoline active agent ed in significantly longer lasting efficacy. This effect is surprising and unexpected, as methoprene is not an adulticide (see Examples 1-3).

In r ment of the invention, it was surprisingly discovered that inclusion of a otinoid active agent such as nitenpyram in the topical compositions of the invention significantly increased the speed of kill of the compositions against fleas. Thus, a topical composition comprising nitenpyram in combination with an isoxazoline active agent and optionally an IGR active agent and/or other oily active agents and/or active agents with low melting points such as permethrin, provide efficacy of at least 90% against fleas as early as 12 hours after administration of the topical formulation and also e long lasting efficacy. In yet other embodiments of the invention, the topical compositions provide efficacy of at least 90% against fleas as early as 9 hours or 6 hours after administration. In one embodiment of the invention, the compositions comprising a combination of nitenpyram and an isoxazoline active agent provide efficacy of at least 90% against fleas as early as 12 hours, 9 hours or 6 hours after treatment and an efficacy of at least 90% for a period of at least 1 month. In other embodiments, the compositions comprising a combination of nitenpyram and an isoxazoline active agent provide efficacy of at least 90% as early as 12 hours, 9 hours or 6 hours after treatment and an efficacy of at least 90% for a period of at least 2 months or at least 3 , or longer. The fast acting and long lasting protection provided by a combination of the neonicotinoid nitenpyram and an isoxazoline active agent is very surprising and unexpected because nitenpyram is only known to be effective when administered orally, as with the product CAPSTARTM Tablets.

In other embodiments, the compositions of the invention may be in the form of - water or water-in-oil emulsions. In some ments the oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these. Suitable emulsifying agents include naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example, sorbitan mono oleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan mono , and the like. In some embodiments, the emulsions may also contain preservatives.

In another embodiment of the ation, the composition of the invention is in the form of a microemulsion. Microemulsions are well suited as the liquid carrier e. Microemulsions MER 11-179PCT are lly quaternary systems comprising an aqueous phase, an oily phase, a surfactant and a co-surfactant. They are usually translucent and isotropic liquids. Microemulsions are composed of stable dispersions of microdroplets of the aqueous phase in the oily phase or sely of roplets of the oily phase in the aqueous phase. The size of these microdroplets is typically less than 200 nm (1000 to 100,000 nm for emulsions). The interfacial film is composed of an alternation of surface-active (SA) and co-surface-active (Co-SA) molecules which, by lowering the interfacial n, allows the microemulsion to be formed spontaneously.

In one embodiment of the oily phase, the oily phase can be formed from mineral or vegetable oils, from unsaturated polyglycosylated glycerides or from triglycerides, or alternatively from mixtures of such nds. In one embodiment of the oily phase, the oily phase comprises of triglycerides. In another embodiment of the oily phase, the triglycerides are medium-chain cerides, for example Cg-Clo caprylic/capric triglyceride. In another embodiment, the oily phase will represent a % v/v range selected from the group consisting of about 1 to about 20%; about 2 to about 15%; about 7 to about 10%; and about 8 to about 9% v/v of the mulsion.

The aqueous phase typically includes, for example water or glycol derivatives, such as propylene , glycol ethers, polyethylene glycols or glycerol. In one embodiment of the glycol tives, the glycol is selected from the group ting of propylene glycol, diethylene glycol monoethyl ether, dipropylene glycol monoethyl ether and mixtures thereof.

Generally, the aqueous phase will represent a proportion from about 1 to about 10% v/v or about 1 to about 4% v/v in the microemulsion.

Surfactants for the mulsion typically include diethylene glycol monoethyl ether, dipropyelene glycol monomethyl ether, polyglycolyzed Cg-Clo glycerides or polyglyceryl-6 dioleate, or a combination of these surfactants. In addition to these surfactants, the co-surfactants include chain alcohols, such as ethanol and propanol. Additionally, poloxamers and Pluronic F127 can be used as surfactants.

Some compounds are common to the three components discussed above, i.e., aqueous phase, surfactant and co-surfactant. However, it is well within the skill level of the practitioner to use different nds for each component of the same formulation.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid MER ll-l79PCT n, and the like. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol, and the like. These compositions may be preserved by the addition of an anti-oxidant such as ic acid or other known preservatives.

Aqueous suspensions may contain the active agents in admixture with excipients suitable for the manufacture of aqueous sions. Such excipients include suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a lly-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, ecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol mono-oleate, or condensation products of ethylene oxide, with partial esters derived from fatty acids and l anhydrides, for example polyethylene sorbitan mono-oleate. The aqueous suspensions may also n one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents.

Colorants may be added to the inventive formulations. Colorants contemplated by the present invention are those commonly known in the art. Specific colorants include, for example, dyes, FD&C Blue #1 Aluminum Lake, caramel, colorant based upon iron oxide or a mixture of any of the foregoing. Especially preferred are organic dyes and titanium dioxide. Preferred ranges include from about 0.01% to about 2% (w/v), more ably from about 0.01% to about 0.5% (w/v).

In red ment, the compositions of the invention are in the form of a spot-on ation that is applied to a localized area on an animal, rather than the entire coat of the animal or a large portion of the animal’s coat. In one ment of a localized region, the location is between the shoulders. The spot-on formulation according to the present ion e long-lasting and broad-spectrum efficacy against ectoparasites and/or endoparasites when the solution is applied to the animal. The spot-on formulations provide for topical administration of a concentrated solution, suspension, microemulsion or emulsion for intermittent application to localized area on the animal, generally n the two shoulders.

Spot-on ations are well known techniques for topically delivering certain MER 11-179PCT rasitic agents to a limited area of the host. However, not all compounds are suited for formulation in spot-on formulations because the physicochemical characteristics of the active agent may not allow effective distribution of the compound topically or transdermally. US.

Patent Nos. 5,045,536, 6,395,765; 6,096,329; 7,262,214; 6,426,333; 6,482,425; 6,962,713; 6,998,131; and 7,531,186, all incorporated herein by reference, describe spot-on formulations.

WO 01/957715, also incorporated herein by reference, describes a method for controlling rasites in small s as well as interrupting or preventing the diseases caused by arthropods in small rodents, which comprise applying l ations, such as spot-on itions, to the skin, or hair of the rodents.

Spot-on formulations may be prepared by dissolving the active ingredients into the pharmaceutically or veterinary acceptable vehicle. Alternatively, the n formulation can be prepared by encapsulation of the active ingredients to leave a film of the therapeutic agent on the surface of the animal. These formulations will vary with regard to the weight of the therapeutic agent in the combination depending on the species of host animal to be treated, the ty and type of infection and the body weight of the host.

For spot-on formulations, the pharmaceutically acceptable carrier may be a liquid carrier vehicle as described herein, and other carriers described in the art, for example in US. Patent No. 6,395,765 and other patents listed in the previous paragraph. In some embodiments, the liquid carrier vehicle can optionally contain a crystallization tor such as the crystallization inhibitors described below, or mixtures thereof, to inhibit the formation of crystals or precipitate of the active components.

The narily acceptable carrier will generally se a diluent or e in which the active agents are soluble. It will be apparent to those of skill in the art that the carrier or t of the topical compositions must be able to deliver the active agents to the targeted location without the active agents precipitating from solution or forming crystals. In some embodiments, the carrier or diluent of the compositions will be suitable to avoid precipitation or crystallization of the active agents. In other embodiments, the compositions may include a crystallization inhibitor component in addition to the carrier or diluent.

Crystallization inhibitors which are useful for the invention include but are not d to: (a) polyvinylpyrrolidone, polyvinyl alcohols, copolymers of vinyl acetate and of vinylpyrrolidone, 2-pyrrolidone including ylpyrrolidone, dimethylsulfoxide, polyethylene MER ll-l79PCT glycols, co-polymers of polyoxyethylene and polyoxypropylene, benzyl l, mannitol, glycerol, sorbitol or polyoxyethylenated esters of an; lecithin or sodium carboxymethylcellulose; or acrylic derivatives, such as polymers d from c monomers including polyacrylates or polymethacrylates; and, a solvent as described herein that inhibits the crystallization of the active agent, and similar compounds; (b) c tants, such as alkaline stearates (e.g. sodium, potassium or ammonium stearate); calcium stearate or triethanolamine stearate; sodium abietate; alkyl sulfates, which include but are not limited to sodium lauryl e and sodium cetyl sulfate; sodium dodecylbenzenesulfonate or sodium dioctyl sulphosuccinate; or fatty acids (e. g. coconut oil); (c) cationic tants, such as soluble quaternary ammonium salts of formula N+R'R"R"'R""Y_, in which the R radicals are identical or different optionally hydroxylated hydrocarbon ls and Y_ is an anion of a strong acid, such as halide, sulfate and sulfonate anions; cetyltrimethylammonium bromide is one ofthe cationic surfactants which can be used; (d) amine salts of formula N+HR'R"R'" Y", in which the R radicals are identical or different optionally hydroxylated hydrocarbon ls and Y" is the anion of a mineral or organic acid; octadecylamine hydrochloride is one of the cationic surfactants which can be used; (e) non-ionic surfactants, such as optionally polyoxyethylenated esters of sorbitan, e.g. Polysorbate 80, or polyoxyethylenated alkyl ethers; polyethylene glycol te, polyoxyethylenated derivatives of castor oil including hydrogenated castor oil and its tives, polyglycerol esters, polyoxyethylenated fatty alcohols, polyoxyethylenated fatty acids or copolymers of ethylene oxide and of propylene oxide; (f) amphoteric surfactants, such as substituted lauryl compounds of betaine; or (g) a mixture of at least two of the compounds listed in (a)—(f) above.

In one embodiment of the crystallization inhibitor, a crystallization inhibitor pair will be used. Such pairs include, for example, the combination of a film-forming agent of polymeric type and of a surface-active agent. Other llization inhibitor pairs include a polyethylene glycol and a non-ionic surfactant. Additional crystallization pairs including other mixtures are also contemplated. These agents can be selected from the compounds mentioned above as crystallization inhibitor.

In one embodiment of the film-forming agent, the agents are of the polymeric type which MER 11-179PCT include but are not limited to the various grades of polyVinylpyrrolidone, polyvinyl alcohols, polyethylene s and copolymers of Vinyl acetate and of Vinylpyrrolidone.

In one embodiment of the surface-active agents, the agents include but are not limited to those made of non-ionic surfactants. In another embodiment of the surface active agents, the agent is a polyoxyethylenated ester of sorbitan. In yet another embodiment of the surface-active agent, the agents include the various grades of polysorbate, for example Polysorbate 80 and polyoxyethylenated derivatives of castor oil including hydrogenated castor oil derivatives.

In another embodiment of the invention, the film-forming agent and the surface-active agent can be incorporated in similar or identical amounts within the limit of the total amounts of crystallization inhibitor mentioned above.

In some ments, the crystallization inhibitor can be present in a proportion of about 1 to about 30% (w/V). Typically, the crystallization inhibitor may be t in a proportion of about 1% to about 20% (w/V), about 1% to about 10% (w/V), or about 5% to about 15% (w/V). able inhibitors are those whose addition to the formulation inhibits the formation of ls of the active agents when the formulation is applied. In some embodiments, formulations may include compounds that on as crystallization inhibitors other than those listed .

In these embodiments, the ility of a crystallization inhibitor may be determined by testing if it will iently inhibit the formation of crystals so that a sample containing 10% (w/V) of the isoxazoline active agent in a solvent as described above with 10% (w/V) of the crystallization inhibitor will result in less than 20, ably less than 10 crystals when placed on a glass slide at 20 ° C for 24 hours.

In some embodiments of the invention, an emollient and/or spreading and/or film- forming agent may be added to the topical compositions of the invention. Emollients, spreading agents and film forming agents are well known in the art. In various embodiments, the emollients, spreading agents and film forming agents that may be used in the topical itions include the components listed in (a) to (g) above, including polymer tives such as polyVinylpyrrolidone, polyVinyl alcohols and copolymers of Vinyl acetate and Vinylpyrrolidone; anionic surfactants; cationic surfactants; non-ionic surfactants; amphoteric surfactants; amine salts, and ations thereof. In one embodiment, the emollient is used in a proportion of from about 0.1 to about 10%, or about 0.25 to about 5% (w/V).

Optionally, a fragrance may be added to any of the compositions of the invention.

WO 39948 MER 11-179PCT Fragrances which are useful for the invention include but are not d to: (i) carboxylic acid esters such as octyl acetate, isoamyl acetate, isopropyl acetate and isobutyl e; (ii) fragrant oils such as lavender oil.

The inventive formulations may contain other inert ingredients such as idants, preservatives, or pH stabilizers. These compounds are well known in the formulation art.

Antioxidants such as vitamin E, alpha tocopherol, ascorbic acid, ascorbyl palmitate, citric acid, fumaric acid, malic acid, sodium ascorbate, sodium sulfate, sodium metabisulf1te, n- propyl gallate, BHA (butylated y anisole), BHT (butylated y toluene), BHA and citric acid, monothioglycerol, tert-butyl hydroquinone (TBHQ), and the like, may be added to the present formulation. The antioxidants are generally added to the formulation in amounts of from about 0.01 to about 2.0%, based upon total weight of the ation, with about 0.05 to about 1.0% being especially preferred.

Preservatives, such as the parabens (methylparaben and/or propylparaben), are ly used in the formulation in amounts ranging from about 0.01 to about 2.0%, with about 0.05 to about 1.0% being especially preferred. Other preservatives include benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butylparaben, cetrimide, chlorhexidine, butanol, chlorocresol, cresol, ethylparaben, imidurea, methylparaben, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid, thimerosal, and the like. Preferred ranges for these compounds include from about 0.01 to about Compounds which stabilize the pH of the formulation are also contemplated. Again, such compounds are well known to a practitioner in the art as well as how to use these compounds.

Buffering systems include, for example, systems selected from the group consisting of acetic acid/acetate, malic acid/malate, citric acid/citrate, tartaric acid/tartrate, lactic acid/lactate, phosphoric acid/phosphate, e/glycimate, tris, glutamic lutamates and sodium carbonate.

In other embodiments, the topical compositions of the invention may be in the form of a pour-on formulation. Pour-on formulations are described, for example, in US. Patent No. 6,010,710, which is incorporated herein by nce. Some pour-on formulations are MER ll-l79PCT advantageously oily, and generally comprise a t or vehicle and also a solvent (e.g. an c t) for the active ingredient if the latter is not soluble in the diluent. Other pour-on formulations may be in hydrophilic carriers, including in alcohol, glycol or glycol ether based carriers. Pour-on formulations are typically administered to livestock animals such as cattle and sheep. Typically, pour-on formulations are administered to the animal as a stripe to an external surface of the animal, e.g. a stripe from head to tail of the animal. In one embodiment, the process comprises applying the solution to livestock animals before they arrive in the Feed Lot, it being possible for this application to be the final one before the s are slaughtered. lly, the oline(s) active agents are present in the formulation at a concentration of about 1 to about 25% (w/v). In some embodiments of the invention, the isoxazoline active agents are present in the ation as a concentration from about 1 to about % (w/v), about 1 to about 10% (w/v), about 5 to about 15% (w/v), or about 5 to 10% (w/v). In other embodiments, the isoxazoline active agent(s) are present in the compositions at a concentration of about 1 to about 5% (w/v), about 3-6 % (w/v) or about 0.5% to about 2.0% (w/v).

The volume of the topical composition applied is not restricted as long as the amount of substance administered is practical and shown to be safe and effective. lly, the volume applied depends on the size and weight of the animal as well as the concentration of active, the extent of infestation by parasites and the type of administration. For spot-on compositions, the volume applied is typically of the order of about 0.1 ml to about 10 ml, about 0.1 ml to about 5 ml, or about 0.1 to about 1 ml, or, or. In other embodiments, the volume may be about 4 ml to about 7 ml. For larger animals, the volume may be higher including, but not limited to, up to 10 ml, up to 20 ml or higher. In one embodiment of the volume, the volume is on the order of about 0.5 ml to about 1 ml or about 0.5 ml to about 2 ml for cats, and on the order of about 0.3 to about 3 ml or 4 ml for dogs, depending on the weight of the animal.

For the pour-on form of the composition, the volume applied can be of the order of about 0.3 to about 100 mL. In other embodiments, volume applied of the n formulations may be about 1 ml to about 100 ml or about 1 ml to about 50 ml. In still other embodiments, the volume may be about 5 ml to about 50 ml or about 10 ml to about 100 ml.

Dosage forms may contain from about 0.5 mg to about 5 g of a combination of active agents. More typically, the amount of active is present in an amount of from about 1 mg to about MER ll-l79PCT 500 mg of an active agent, about 1 mg to about 100 mg or about 1 mg to about 25 mg. In still other embodiments, the amount of the active agent present in the compositions is about 10 mg about 50 mg or about 10 mg to about 100 mg. In other embodiments, the amount of active agent present in the compositions is about 50 mg to about 200 mg, about 100 mg to about 300 mg, about 100 mg to about 400 mg, about 200 mg to about 500 mg, about 300 mg to about 600 mg, about 400 mg to about 800 mg, or about 500 mg to about 1000 mg.

The compositions of the invention are made by mixing the appropriate amount of the active , pharmaceutically acceptable carrier or diluent and optionally a crystallization inhibitor, antioxidant, preservative, film former, etc., to form a composition of the invention. In some embodiments the ition can be obtained by following the method of making these forms described above by the description of making these forms found in general formulation text known to those in the art, e.g. Remington — The Science and Practice of cy (21” Edition) (2005), Goodman & Gilman’s The Pharmacological Basis of Therapeutics (11th Edition) (2005) and Ansel ’s Pharmaceutical Dosage Forms and Drug Delivery Systems (8th Edition), edited by Allen et al., Lippincott Williams & Wilkins, (2005).

Methods of Treatment In r aspect of the invention, a method for preventing or treating a parasite infestation/infection in an animal is ed, comprising administering to the animal a topical ition comprising an effective amount of at least one isoxazoline active agent together with a pharmaceutically acceptable carrier that is le for application to the skin of the animal. The compositions or formulations of the invention have long-lasting efficacy against ectoparasites (e.g. fleas and ticks) and in certain embodiments may also active against endoparasites that harm s.

In one embodiment of the invention, methods for the ent or prevention of a parasitic infestation or infection in a domestic animal are provided, which comprise administering a topical composition comprising an ive amount of at least one isoxazoline active agent to the . Ectoparasites against which the methods and compositions of the invention are effective include, but are not limited to, fleas, ticks, mites, mosquitoes, flies and lice. In certain embodiments wherein the compositions e one or more additional active agents that are active against al parasites the compositions and methods of the invention may also effective against endoparasites including, but not limited to, cestodes, nematodes, MER ll-l79PCT rms and roundworms of the digestive tract of animals and humans.

In one embodiment for treatment against ectoparasites, the ectoparasite is one or more insect or arachnid ing those of the genera Ctenocephalides, Rhipicephalus, Dermacentor, , Boophilus, mma, Haemaphysalis, ma, Sarcoptes, tes, 0toclectes, Chorioptes, Hypoderma, Damalinia, Linognathus, Haematopinus, Solenoptes, Trichodectes, and Felicola.

In another embodiment for the treatment against ectoparasites, the ectoparasite is from the genera Ctenocephalicles, Rhipicephalus, Dermacentor, Ixodes and/or Boophilus. The ectoparasites treated include but are not limited to fleas, ticks, mites, mosquitoes, flies, lice, blowfly and combinations thereof. Specific examples include, but are not d to, cat and dog fleas (Ctenocephaliclesfelis, Ctenocephalides sp. and the like), ticks (Rhipicephalus sp., Ixodes sp., Dermacentor sp., Amblyoma sp. and the like), and mites (Demodex sp., Sarcoptes sp., Otodectes sp. and the like), lice (Trichodectes sp., Cheyletiella sp., Lignonathus sp., and the like), mosquitoes (Aecles sp., Culex sp., Anopheles sp., and the like) and flies (Hematobia sp. ing Haematobia irritans, Musca sp., Stomoxys sp. including Stomoxys calcitrans, Dematobia sp., Cochliomyia sp., and the like).

Additional examples of ectoparasites include but are not limited to the tick genus Boophilus, especially those of the species microplus (cattle tick), decoloratus and annulatus; myiases such as Dermatobia hominis (known as Beme in Brazil) and Cochliomyia hominivorax (greenbottle); sheep s such as Lucilia sericata, Lucilia cuprina (known as blowfly strike in Australia, New Zealand and South Africa). Flies proper, namely those whose adult tutes the parasite, such as Haematobia irritans (horn fly) and Stomoxys calcitrans (stable fly); lice such as athus vituli, etc.; and mites such as Sarcoptes scabiei and Psoroptes ovis. The above list is not exhaustive and other ectoparasites are well known in the art to be harmful to animals and humans. These include, for example ing dipterous .

In some embodiments of the invention, the composition can also be used to treat t endoparasites such as those ths selected from the group consisting ofAnaplocephala, Ancylostoma, Anecator, Ascaris, Capillaria, Cooperia, Dipyliclium, Dirofilaria, Echinococcus, Enterobius, Fasciola, Haemonchus, 0esophagostumum, Ostertagia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, and Trichostrongylus, among others.

In one embodiment, the ion provides methods for the treatment and prevention of 2012/054719 MER ll-l79PCT parasitic infections and infestations of animals (either wild or domesticated), ing livestock and companion animals such as cats, dogs, horses, birds including chickens, sheep, goats, pigs, turkeys and cattle, with the aim of ridding these hosts of parasites commonly encountered by such animals.

In a preferred embodiment, the invention provides methods and compositions for the treatment or prevention of parasitic ions and infestations in companion animals including, but not limited to, cats and dogs. The s and compositions are particularly effective for preventing or treating tic infestations of cats and dogs with fleas and ticks.

In another preferred embodiment, the methods and itions of the invention are used for the treatment or prevention of parasitic infections and infestations in cattle or sheep. When treating livestock animals such as cattle or sheep, the methods and compositions are ularly effective t Rhipz'cephalus (Boophilus) microplus, Haematobz'a irritans (horn fly), Stomoxys calcitrans (stable fly), and sheep myiases such as Lucilz’a sericata, Lucilz’a cuprz’na (known as blowfly strike in Australia, New Zealand and South Africa).

The terms “treating” or “treat” or “treatment” are intended to mean the application or administration of a composition of the invention to an animal that has a parasitic infestation for the eradication of the parasite or the reduction of the number of the parasites ing the animal undergoing treatment. It is noted that the compositions of the invention may be used to prevent such a parasitic infestation.

The compositions of the ion are administered in parasiticidally effective amounts which are which are suitable to control the parasite in question to the desired extent, as described below. In each aspect of the invention, the compounds and compositions of the invention can be applied against a single pest or ations f The compositions of the invention may be administered continuously, for treatment or prevention of parasitic infections or infestations. In this manner, the compositions of the invention deliver an effective amount of the active compounds to the animal in need thereof to control the target parasites. By “effective amount” is intended a sufficient amount of a composition of the invention to eradicate or reduce the number of parasites infesting the animal.

In some embodiments, an effective amount of the active agent achieves at least 70% efficacy against the target parasite. In other embodiments, an effective amount of the active agent achieves at least 80%, or at least 90% efficacy against the target pests. ably, an effective MER 11-179PCT amount of the active agent will achieve at least 95%, at least 98% or 100% efficacy t the target parasites.

Generally, a dose of from about 0.001 to about 100 mg per kg of body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but, of course, there can be instances where higher or lower dosage ranges are indicated, and such are within the scope of this invention. It is well within the routine skill of the practitioner to ine a particular dosing regimen for a specific host and te.

In some embodiments for companion animals, the dose of the isoxazoline active agent administered from the topical compositions of the invention is between about 0.1 to about 30 mg per kg of body weight. More typically the dose of the isoxazoline active agent administered is about 0.5 to about 20 mg/kg or about 0.5 to about 15 mg/kg body weight. Preferably, the dose of the isoxazoline active agent stered is about 0.5 to about 10 mg/kg, about 0.5 to about 8 mg/kg or about 0.5 to about 5 mg/kg of body weight.

In certain embodiments for the treatment and prevention of parasite infestations and ions in cats, the dose of the isoxazoline active agent administered will be about 0.5 to about 2 mg/kg of body weight, ably about 1 mg/kg of bodyweight. In other embodiments for the very long lasting treatment and protection of cats t parasitic infestations or infections a dose of about 2 to about 15 mg/kg of bodyweight or preferably about 5 to about 15 mg/kg of bodyweight will be administered.

In some embodiments for the treatment and protection of dogs from parasitic infestations and infections, a dose of about 2 to about 15 mg/kg of bodyweight of the isoxazoline active agent will be administered. In other embodiments, a dose of about 2 to about 8 mg/kg or about 2 to about 5 mg/kg of bodyweight will be administered.

In other embodiments for the treatment of livestock animals such as cattle or sheep, doses of the isoxazoline active agent administered may be about 1 to about 30 mg/kg of body weight.

More typically the doses administered will be about 1 to about 20 mg/kg or about 1 to about 15 mg/kg. Preferably, a dose of the isoxazoline active agent administered to livestock animals will be about 1 to about 10 mg/kg of body .

Higher amounts may be provided for very prolonged release in or on the body of the . In another treatment embodiment, the amount of active agents for birds and other animals which are small in size is greater than about 0.01 mg/kg, and in r embodiment for WO 39948 MER ll-l79PCT the treatment of small-sized birds and other animals, the amount of is between about 0.01 and about 20 mg/kg of weight of animal. More typically the dose of the isoxazoline for sized animals and birds is about 0.5 to about 15 mg/kg, about 0.5 to about 10 mg/kg of body weight, or about 0.5 mg/kg to about 5 mg/kg of body weight.

In one embodiment of the method of use in dogs or cats, a composition comprising an oline nd has an efficacy against fleas and/or ticks of at least about 90.0% or higher for about 1 month, or longer. In another embodiment, the compositions of the invention provide an efficacy against fleas and/or ticks of at least 95.0% or higher for about 30 days, or longer.

In another embodiment, the l compositions of the invention provide an efficacy against fleas and/or ticks in cats and dogs of at least about 80% for two , or longer. In another embodiment, the topical itions provide efficacy against fleas and/or ticks in cats and dogs of about 90% for about two months, or longer. In still another embodiment, the compositions provide an efficacy of about 95% for about 2 months or longer.

In another embodiment, the composition has an efficacy of at least about 80% against fleas and/or ticks for about 3 months, or . In still another embodiment, the topical compositions of the ion provide an efficacy of at least about 90% against fleas and/or ticks for 3 months or longer. In yet another embodiment, the topical compositions of the invention provide an efficacy of at least about 95% against fleas and/or ticks for 3 months or longer. In still another embodiment, the topical itions of the invention provide an efficacy against fleas and/or ticks in cats and/or dogs of at least 80% or at least 90% for about 3 months to about 6 months or longer.

In one embodiment of the invention, the topical spot-on compositions of the invention are administered to the animal over a localized region of the animal, e. g. between the two shoulders.

In one embodiment of the invention, the localized region has a surface area of about 10 cm2 or larger. In another embodiment of the invention, the localized region has a surface area of between about 5 and about 10 cm2, or smaller.

In another ment of the invention, the pour-on topical compositions of the invention will be administered in a line along the back of the animal approximately between the shoulders and the hind quarters.

The solutions according to the invention may be d using any means known per se, e. g. using an applicator gun or a metering flask, pipette, syringes, roll on, droppers, capsules, foil MER ll-l79PCT packages, vials, twist tip containers, metered-dose aerosols or sprays and other single dose and multi-dose containers.

In another aspect of the invention, a kit for the treatment or prevention of a parasitic infestation in an animal is provided, which comprises at least one oline active agent together with a pharmaceutically acceptable carrier and a dispensing device for topical application of the composition. The dispensing device may be a pipette, syringes, roll on, droppers, capsules, foil packages, vials, twist tip containers, d-dose ls or sprays and other single dose and multi-dose containers, which includes an effective dose of each active agent in the ceutically acceptable carrier or diluent.

An important aspect of the invention is to provide a multiple-use container sing a topical composition of the invention, from which accurate single dose aliquots of the long lasting topical formulations may be administered. The formulation must remain stable with repetitive exposure to the outside environment, particularly oxygen and water. This embodiment may be particularly useful with the very long lasting ations of the invention that e administration to an animal infrequently, such as once every 3-6 , or similar. Some solvents such as ethers (including DMI, Transcutol® and the like) give rise to peroxides, which then yield s and aldehydes that may be further degraded to acids. The presence of acids may contribute to the degradation of acid hydrolysis-susceptible molecules, including isoxazoline active . Thus, formulation stability is particularly ant for the multi-dose container application, where the formulations can be exposed to oxygen and water during le rounds of opening and g. Importantly, it was found that the use of certain antioxidants described , including BHT and BHA, efficiently inhibit the degradation of the active agent in ether solvents. For example, a 12% (w/v) solution of Compound A in DMI exhibited no significant change in assay over the course of an eleven week accelerated stability study at 50 °C in clear glass containers. In other embodiments, antioxidants such as vitamin E, alpha tocopherol, ascorbic acid, ascorbyl palmitate, citric acid, filmaric acid, malic acid, sodium ascorbate, sodium metabisulfate, sodium metabisulfite, n-propyl gallate, BHA (butylated hydroxy anisole), BHT (butylated hydroxy toluene), BHA and citric acid, monothioglycerol and the like, may be added to the topical compositions to inhibit the formation of oxidative species.

The antioxidants are generally added to the formulation in amounts of from about 0.01 to about 2.0%, based upon total weight of the formulation, with about 0.05 to about 1.0% being especially MER ll-l79PCT preferred.

EXAMPLES The invention is fiarther described by the following non-limiting examples which fiarther illustrate the invention, and are not intended, nor should they be interpreted to, limit the scope of the invention.

Formulation Examples Liquid es suitable for topical isoxazoline-containing ations for control of parasites were investigated. As a non-limiting example, the isoxazoline compound 4-[5-[3- chloro(trifluoromethyl)phenyl]-4,5-dihydro(trifluoromethyl)isoxazolyl]-N-[2-oxo [(2,2,2-trifluoroethyl)amino]ethyl]-l-naphthalanecarboxamide (Cmpd. A), was investigated for topical delivery to animals, including cats, dogs and livestock animals such as cattle.

Formulations comprising an isoxazoline nd in combination with one or more additional active agents, including (S)-methoprene, oxyfen and yram, were also ed and tested. ations were prepared with a variety of liquid carrier vehicles and evaluated for effectiveness to control ectoparasites, particularly fleas and ticks in cats and dogs, and ticks, mites and lice in cattle. Solvent systems comprising either one solvent, including a diester of a dicarboxylic acid and/or an ether such as dimethyl isosorbide, or a combination of solvents including a diester of a oxylic acid, specifically diethyl sebacate, and at least a second solvent(s) are encompassed by the invention. In various embodiments, formulations comprising a single solvent such as DES or DMI or a combination of solvents were investigated. Solvents combined with a diester of a dicarboxylic acid include, but are not limited to: l) a propylene glycol ester or ether, including PG monocaprylate, PG caprylate, PG monolaurate, PG dicaprylate/dicaprate, PG caprylic/capric cerides (LABRASOL®) or a combination thereof; 2) an ether (e.g. yl bide); 3) a second ester (triacetin, lauryl lactate); 4) a fatty acid ester including, but not limited to, isopropyl palmitate, isostearyl lactate, dibutyl adipate, dibutyl sebacate, octyl ate, polyethyleneglycol stearate and yl octanoate; 5) a glycol or polyglycol ether such as Transcutol®, PEG 400 and the like; 6) an oil such as mineral oil, diglycerides, triglycerides, jojoba oil, lecithin and castor oil; 7) a long chain aliphatic alcohol MER ll-l79PCT such as isostearyl alcohol; and 8) mixed esters e and carboxylic acids, including sucrose acetate isobutyrate (SAIB) and the like.

In other embodiments, the topical compositions of the invention se Transcutol®, glycerol formal, triacetin, propylene carbonate, benzyl alcohol or DMI.

Non-limiting formulations comprising an isoxazoline compound (Cmpd. A) alone or in combination with the miting additional active agents (S)-methoprene, pyriproxyfen and nitenpyram are provided in below.

Formulation l - Add diethyleneglycol monoethyl ether (Transcutol®) (50% of volume required); Polysorbate 80 and Ethanol are added; the BHA, BHT, povidone l7, and Cmpd. A are then added and mixed until dissolved, and the mixture is QS with Transcutol®.

Cmpd. A ' 3.7, 6.0 w/v (S)-methoprene ' 9.0 w/v Polysorbate 80 5.0 w/v Ethanol Spreading agent 10.0 v/v Butylated hydroxyanisole Antioxidant 0.02 w/v Butylated hydroxy e 0.01 w/v Povidone K- 1 7 Thickener 5 .0 w/v lene glycol hyl ether Solvent QS Formulation 2 - Add glycerol formal (GF, 50% of required volume), add Cmpd. A, dissolve; add DMI; add (s)-methoprene; QS GF.

Glycerol formal (GF) Spreading agent ation 3 - Add diisopropyl adipate (DIPA, 50% of required volume), add Cmpd. A, dissolve; add (s)—methoprene; QS DIPA MER ll-l79PCT Ingredients Function % Cmpd. A Active 3.7, 6.0 W/v (S)-meth0prene Active 9.0 W/v Diisopropyl adipate (DIPA) Spreading agent QS Formulation 4 - Add diethyl sebacate (DES 50% of required volume); add PG rnonolaurate; add Cmpd. A, dissolve; add (S)-methoprene; QS DES.

Ingredients Function % Cmpd. A Active 6.0 W/v (S)-meth0prene Active 9.0 W/v Propylene glycol rnonolaurate Permeation enhancer 25.0 v/v DES ing agent QS Formulation 5 - Add DES (50% of ed volume); add PG monocaprylate; add Cmpd. A, dissolve; add (S)-methoprene; QS DES.

Ingredients Function % Cmpd. A Active 6.0 W/v (S)-meth0prene Active 9.0 W/v Propylene glycol monocaprylate Permeation enhancer 25.0 v/v ol 90) DES Spreading agent QS Formulation 6 - Add DIPA (50% of required ); add Ethyl hexyl pelargonate; add Cmpd.

A, dissolve; add (S)-methoprene; QS DIPA ients Function % Cmpd. A Active 6.0 W/v (S)-meth0prene Active 9.0 W/v Ethyl hexyl pelargonate Permeation enhancer 25.0 v/v DIPA Spreading agent QS MER ll-l79PCT Formulation 7 - Add DIPA (50% of ed volume); add diisopropyl sebacate; add silicone fluid; add Cmpd. A, ve; add (S)-methoprene; QS DIPA Ingredients Function % Cmpd. A Active 6.0 W/v (S)-methoprene Active 9.0 W/v Diisopropyl sebacate Permeation enhancer 25.0 v/v Silicone fluid ing agent v/v DIPA Spreading agent QS Formulation 8 - Add Miglyol 840 (50% of required volume); add lauryl lactate; add Cmpd. A, dissolve; add (S)-methoprene; QS Miglyol 840 Ingredients Function % Cmpd. A Active 6.0 W/v thoprene Active 9.0 W/v Lauryl lactate Permeation enhancer 25.0 v/v Miglyol 840 Spreading agent/ QS permeation enhancer Formulation 9 - Add Miglyol 840 (50% of required volume); add triacetin; add Cmpd. A, dissolve; add (S)-methoprene; QS Miglyol 840 ients Function % Cmpd. A Active 6.0 W/v (S)-methoprene Active 9.0 W/v Triacetin Permeation enhancer 25.0 v/v Miglyol 840 Spreading agent/ QS permeation enhancer Formulation 10 - Add Miglyol 840 (50% of required volume); add Cmpd. A, ve; add (S)- methoprene; QS Miglyol 840 Ingredients Function % MER PCT Cmpd. A Active 6.0 W/v (S)-methoprene 9.0 W/v Miglyol 840 Spreading agent/ QS permeation enhancer Formulation ll - Add DES (50% of required volume); add Cmpd. A, dissolve; add (S)- methoprene; QS DES Ingredients Function % Cmpd. A Active 3.0, 4.5, 6.0 W/v (S)-methoprene Active . W/v DES Spreading agent/ permeation enhancer Formulation 12 - Add DES (50% of required volume); add Cmpd. A, ve; QS DES Ingredients Function % Cmpd. A Active . W/v DES ing agent/ QS permeation enhancer Formulation l3 - Add DES (50% of required volume); add PG prylate; add Cmpd. A, dissolve; QS DES.

Propylene glycol monocaprylate Permeation enhancer (Capryol 90) DES Spreading agent Formulation l4 - Add DES (30% of required volume); add PG dicaprylate/dicaprate and PG monocaprylate; add Cmpd. A, dissolve; add (S)-methoprene QS DES. 2012/054719 MER ll-l79PCT Cmpd. A Active 12.0 W/v (S)-methoprene Active 9.0% W/v Propylene glycol dicaprylate/dicaprate Permeation enhancer 25.0 V/v (Capryol PGMC) Propylene glycol monocaprylate (Capryol 90) Permeation enhancer 25.0 v/v DES Spreading agent QS Formulation l5 - Add DES (50% of required volume); add, with stirring, lauryl lactate; add Cmpd. A, dissolve; QS DES Ingredients Function Lauryl Lactate Permeation enhancer 25.0 v/v DES Spreading agent QS Formulation l6 - Add DIPA (50% of required volume); add DMI; add Cmpd. A, ve; QS DIPA Ingredients Function % Dimethyl isosorbide Permeation enhancer 25 v/v Formulation l7 - Add DES (50% of ed volume); add DMI; add Cmpd. A, dissolve; QS ation 18 — Add DES (40% of required volume); add DMI; add Cmpd. A, dissolve; QS WO 39948 MER 11-179PCT Ingredients Function Spreading agent 40% Dimethyl bide (DMI) Permeation enhancer QS 100% v/v Formulation 19 — Add DIPA (50% of required volume); add triacetin; add Cmpd. A, dissolve; QS DIPA Ingredients Function % Cmpd. A Active 6.0 W/v Triacetin Permeation enhancer 25 v/v Diisopropyl adipate Spreading agent QS 100% Formulation 20 — Add DES (60% of required volume); add mineral oil, medium; add Cmpd. A, dissolve; QS DES Cmpd. A Active mineral oil, medium Substantivity Agent Spreading agent QS 100% Formulation 21 — Add DES (60% of required volume); add l oil, light; add Cmpd. A, dissolve; QS DES Cmpd. A Active mineral oil, light Substantivity Agent Spreading agent QS 100% Formulation 22 - Add DES (60% of required volume); add, with ng, Transcut01®; add Cmpd. A, mix until dissolved; add SAIB; QS with DES Cmpd. A Active 6.0 W/v MER 11-179PCT Transcutol® Solvent 20 w/v Sucrose acetate isobutyrate (SAIB) lled release agent 5 w/v DES Spreading agent QS 100% Formulation 23 - Add DES (60% of required volume); add, with stirring, Transcutol®; add, with stirring, PEG 400; add Cmpd. A, mix until dissolved; QS with DES Formulation 24 - Add utol® (60% of required volume); add, with stirring, PEG 400; add Cmpd. A, mix until dissolved; QS Transcutol® Ingredients Function % Cmpd. A Active 6.0 w/v PEG 400 lled release agent 5 w/v Transcutol Solvent & Spreading agent QS Formulation 25 - Add DES (60% of required volume); add, with stirring, Transcutol®; add, with stirring, PEG 400; add Cmpd. A, mix until dissolved; QS with DES ients Function % ML Cmd. A Active 6.0 w/v Transcutole Solvent 20 w/v PEG 400 Controlled release aent 10 w/v DES Spreading agent QS Formulation 26 - Add DES (60% of required volume); add, with stirring, PEG 400; add Cmpd.

A, mix until dissolved; QS with DES Ingredients Function Cl’nod.A Active PEG 400 Solvent and Controlled release aent So_readin a_ent 2012/054719 MER ll-l79PCT Formulation 27 - Add GF (50% of required volume), add Cmpd. A, ve; add nitenpyram, dissolve; add DMI; QS GF.

Glycerol formal Spreading agent Formulation 28 - Add DMI (50% of required ), add Cmpd. A, dissolve; add nitenpyram, dissolve; add (S)-methoprene and dissolve; QS with DMI.

Ingredients Function % 0.5-2 W/v Nitenpyram 2-8 W/v (S)-methoprene 7-10 W/v Dimethyl isosorbide Solvent QS Formulation 29 - Add DMI (50% of required volume), add Cmpd. A, dissolve; add nitenpyram, dissolve; add pyriproxyfen and dissolve; QS DMI.

Cmpd. A ' 0.5-2 W/v Nitenpyram 2-8 W/v pyriproxyfen 3-6 W/v Dimethyl isosorbide Solvent QS Formulation 30 - Add Transcutol® (50% of required volume), add Cmpd. A, dissolve; add nitenpyram, dissolve; add oxyfen and dissolve; QS Transcutol®.

Ingredients Function Cmpd A Active MER ll-l79PCT Formulation 31 - Add GF (50% of required volume), add Cmpd. A, dissolve; add nitenpyram, dissolve; add pyriproxyfen and dissolve; QS GF.

Formulation 32 - Add triacetin (50% of required volume), add Cmpd. A, dissolve; add nitenpyram, dissolve; add pyriproxyfen and dissolve; QS triacetin. ients Function % Nitenpyram pyriproxyfen triacetin t Formulation 33 - Add ene carbonate (50% of required volume), add Cmpd. A, dissolve; add nitenpyram, dissolve; add pyriproxyfen and dissolve; QS propylene carbonate.

Ingredients Function % Cmpd. A 0.5-2 W/v Nitenpyram 2-8 W/v oxyfen 3-6 W/v Propylene carbonate t QS Cmpd. A was found to be stable in at least DES, DIPA, DMI, triacetin, GF and propylene carbonate (at 50°C in glass bottles).

Biological Efficacy Examples Example 1: cy of a Spot-on Composition Comprising a Combination of Cmpd. A and (S)- methoprene Against Dermacentor variabilis Ticks and Ctenocephalz’desfelz’s Fleas in Dogs MER ll-l79PCT Twenty eight beagle dogs were studied to determine the effectiveness of a combination of Cmpd. A and (S)-methoprene when administered once as a topical solution against d infestations ofDermacem‘or variabilis and Ctenocephalz'desfelis.

Four Treatment Groups containing seven dogs each were formed. Dogs in Group 1 were untreated (control). Dogs in Groups 2, 3 and 4 were treated topically with spot-on compositions sing 3.7% (w/v) Cmpd. A and 9% (w/v) (S)-methoprene administered to deliver 2.5 mg/kg Cmpd. A and 6 mg/kg (S)-methoprene (Group 2: Transcutol with 10% (w/v) ethanol, 5% (w/v) TWEEN 80 and 5% (w/v) polyvinylpyrrolidone; Group 3: DM1 and glycerol formal (GF); and Group 4: DIPA). All dogs were treated once on Day 0.

All dogs were infested with approximately 100 C. felis on Days -l, 8, 15, 22, 29, 35, 43 and 57, and for all Groups except 5, on Day 71. All dogs were also infested with approximately 50 D. variabilis on Days -l, 7, 14, 21, 28, 34 and 42. Fleas were counted upon removal on Day - 6. Both ticks and fleas were counted upon removal on Days 2, 9, 16, 23, 30, 36 and 44. Fleas only were counted upon removal for all Treatment Groups on Day 58 and for all Treatment Groups except 5 on Day 72. Flea efficacy is listed in Table l and tick efficacy is listed in Table 2 below.

Blood samples were collected from all dogs in the study on Days -6, 0 (at 4 h and 12 h), l, 2, 9, 16, 23, 30, 36, 44, 51, 58, 64, 72, 79 and 86. Plasma samples were ed for the tration of Compound A using an LC/MS/MS analytical method that was GLP ted for the purpose.

Percent ion (also referred as efficacy) against fleas was 100% through and including Day 30 for all treatment groups (see Table 1). Percent reduction against fleas was above 95% through Day 58 for Group 3.

The percent reduction against ticks was >94% through and including Day 23 (48 hours infestation, see Table 2). Percent ion was >92% for Groups 6 and 7 on Day 30.

These study data trate that l formulations comprising Cmpd. A and (S)- methoprene in three different carrier vehicles provided 100% percent reduction for fleas through Day 30 for all treated groups. Tick efflcacy was 100% on Days 9 and 16 and two treatment groups (6 and 7) were 292% on Day 30.

MER ll-l79PCT Table 1: Efficacy of a Spot-on Composition Comprising a Combination of Cmpd. A and (S)- methoprene Ctenocephalz’desfelis Treatment Group % Reduction Fleas Day Day Day Day Day Day Day Day Day 2 9 16 23 30 36 44 58 72 Group 2 100.0 100.0 100.0 100.0 100.0 100.0 86.5 33.2 -- %Reduction Group 3 100.0 100.0 100.0 100.0100.0 100.0 99.6 98.5 89.0 %Reduction Group 4 100.0 100.0 100.0 100.0100.0 99.8 95.2 89.3 68.9 %Reduction Table 2: Efficacy of a n Composition sing a Combination of Cmpd. A and (S)- methoprene Against Dermacem‘or variabilis Ticks Treatment Group % Reduction Ticks Day Day Day Day Day Day Day 2 9 16 23 30 36 44 Group2 %Reduction 89.0 00 94.8 65.0 23.3 20.7 Group3 %Reducti0n 88.5 10001000 99.2 94.6 88.3 77.6 Group4 %Reducti0n 84.3 10001000 97.2 92.0 52.2 57.0 Example 2: Efficacy of Spot-on Formulations Containing Compound A and (S)—methoprene Against Ctenocephalidesfelis.

Following the initial s described in e 1, additional l formulations comprising Compound A in combination with an insect growth regulator, (S)-methoprene, in carrier vehicles comprising both a spreading solvent and a permeation t were studied.

Thus, the efficacy of five different topical formulations comprising Compound A and (S)- methoprene against the cat flea (Ctenocephalz’des felis) in dogs was determined using to a protocol similar to that of Example 1.

Seven Treatment Groups with four dogs each were evaluated. Dogs in Group 1 were ted, and served as a control group. Dogs in Groups 2-6 were treated topically with MER 11-179PCT formulations comprising Cmpd. A and thoprene in different carrier vehicles administered at 4.0 mg/kg Cmpd. A + (S)—methoprene administered at 6 mg/kg (Group 2: Miglyol 840; Group 3: DIPA / 25% triacetin; Group 4: DIPA / 25% DMI; Group 5 DIPA / 25% ethyl hexyl pelargonate; and Group 6: DIPA + 25% diisopropyl te + 3% silicone fluid). Dogs in Group 7 were treated at a dose level of 7.0 mg/kg Compound A + thoprene at 6 mg/kg with a formulation comprising DIPA + 25% diisopropyl sebacate + 3% silicone fluid. The concentrations of Compound A and (S)-methoprene in formulations of Groups 2-5 were 6.0% (w/v) and 9.0% (w/v), respectively, and the concentration of Compound A and (S)-methoprene in formulations of Groups 6 and 7 were 10.5% (w/v) and 9% (w/v), respectively.

Dogs were infested with approximately 100 C. felis fleas on Day -1. Dogs were d with the respective topical formulations on Day 0. Fleas were d and counted on Day 2. ations with about 100 fleas were also made on Days 8, 15, 22, 29, 36 and 43. Fleas were combed and counted 24 :: 3 hours after infestation on Days 9, 16, 23, 30, 37 and 44.

Table 3 below provides the % efficacy for each of the topical formulations. As demonstrated by the data, each of the formulations was highly efficacious against the cat flea through at least 44 days.

Table 3: Efficacy of Spot-on Composition Against Ctenocephalz’desfelz’s Geometric Mean Flea Count / % Reduction Treatment Group Day2 Day9 Day Day Day Day Day 16 23 30 37 44 GroupZ %Reduction 100.0 100.0 100.0 100.0 100.0 100.0 98.6 Group3 %Reduction 100.0 99.6 100.0 100.0 100.0 100.0 100.0 Group4 %Reduction 100.0 100.0 100.0 100.0 100.0 100.0 100.0 Groups %Reduction 100.0 100.0 100.0 100.0 100.0 100.0 100.0 Group6 %Reduction 99.6 100.0 100.0 100.0 100.0 100.0 100.0 Group 7 MER ll-l79PCT %Reduction 100.0 100.0 100.0 100.0 100.0 100.0 100.0 Example 3: y of Spot-on Formulations Containing Compound A and thoprene Against Rhipz'cephalus Sanguineus.

In another study, the efficacy against ticks of additional topical formulations sing isoxazoline Compound A in combination with (S)-methoprene in r carrier vehicles comprising both a ing solvent and a permeation-enhancing solvent was determined. Thus, six topical formulations comprising nd A and (S)-methoprene were tested for efficacy against ha’pz’cephalus Sanguineus ticks in beagle dogs according to a protocol similar to that of Example 1.

Seven Treatment Groups with four dogs each were evaluated. Dogs in Group 1 were untreated, and served as a control group. Dogs in Groups 2-6 were treated topically with Cmpd.

A in ent carrier vehicles administered at 4.0 mg/kg + (S)-methoprene administered at 6 mg/kg (Group 2: Miglyol